


(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
14 September 2006 (14.09.2006)

PCT

(10) International Publication Number
WO 2006/096737 A2

(51) International Patent Classification: Not classified

(21) International Application Number:
PCT/US2006/008143

(22) International Filing Date: 7 March 2006 (07.03.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Date:
00/659,334 7 March 2005 (07.03.2005) US(71) Applicants (for all designated States except US): **THE TRUSTEES OF BOSTON UNIVERSITY** [US/US]; One Sherborn Street, Boston, MA 02215 (US); **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 201 West 7th Street, Austin, TX 78701 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **FARRER, Lindsay, A.** [US/US]; 18 Higley Road, Ashland, Ma 01721 (US); **EDWARDS, Albert, O.** [US/US]; 3215 Princess Lane, Dallas, TX 75229 (US).(74) Agents: **EISENSTEIN, Ronald, J. et al.**; Nixon Pechony LLP, 100 Summer Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: DIAGNOSTIC AND THERAPEUTIC TARGET FOR MACULAR DEGENERATION



(57) Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with ocular diseases and disorders, such as age-related macular degeneration (AMD). In particular, the present invention relates to methods for determining an individual's susceptibility to ocular disorders such as AMD by screening for mutations and/or polymorphisms in the human complement factor H (CFH) gene or gene product that confer susceptibility to such disorders. Also encompassed in the present invention are nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of treatment following detection of susceptibility.

DIAGNOSTIC AND THERAPEUTIC TARGET FOR MACULAR DEGENERATION

CROSS REFERENCE TO RELATED APPLICATIONS

[001] This application claims the benefit under 35 U.S.C. 119(e) of U.S. Provisional Patent Application Serial No. 60/659,334, filed March 7, 2005, the contents of which are herein incorporated by reference in their entirety.

GOVERNMENT SUPPORT

[002] This invention was made with Government Support under Contract Number EY014467, awarded by the National Institutes of Health. The Government has certain rights in the invention.

FIELD OF THE INVENTION

[003] The present invention is directed to methods for the diagnosis and determination of susceptibility for ocular disorders such as age-related macular degeneration, as well as methods for screening for novel therapies and methods for improved therapies for the treatment of age-related macular degeneration.

BACKGROUND OF THE INVENTION

[004] Age-related macular degeneration (AMD) is a leading cause of blindness in older individuals (1). It is a late-onset, complex trait with hereditary, lifestyle, and medical risk factors (2). The condition typically begins to be seen in the fifth decade of life with small yellow deposits external to the outer retina and retinal pigment epithelium (RPE) called drusen. Large numbers of drusen and clinical features of damage to the RPE markedly increase the risk of complications (atrophy of the RPE and abnormal neovascularization of the outer retina), leading to severe vision loss (1).

[005] Although the primary pathogenic mechanisms of AMD remain unknown, there is strong evidence that genetics plays a role (3-9). The first locus for AMD (*ARMD1*) was reported in a single extended family linked to chromosome 1q25.3-31.3 (5).

[006] While it has been proposed that a threshold event occurs during normal aging which leads to AMD, the sequelae of biochemical, cellular, and/or molecular events leading to the development of AMD are poorly understood. Drusen, pathological deposits that form between the retinal pigmented epithelium (RPE) and Bruch's membrane, are significant risk factors for the development of AMD. The characterization of the molecular composition of drusen has suggested that proteins associated with inflammation and immune-mediated processes are prevalent among drusen-associated constituents. For example, proteins and transcripts that encode a number of these molecules have been detected in retinal, RPE, and choroidal cells. Hageman et al., *Prog Retin Eye Res.* 2001 Nov;20(6):705-32.

[007] More specifically, it has been suggested that combined events of cellular dysfunction and death, drusen deposition and activation of immunomodulatory processes at the level of the RPE-choroid-retina complex are key elements that participate in AMD. Cellular remnants and debris derived from degenerate RPE cells become sequestered between the RPE basal lamina and Bruch's membrane. This cellular debris has been suggested to constitute a chronic inflammatory stimulus, and a potential "nucleation" site for drusen formation. The entrapped cellular debris then becomes the target of encapsulation by a variety of inflammatory mediators, some of which are contributed by the RPE and, perhaps, other local cell types; and some of which are extravasated from the choroidal circulation. One set of immunomodulatory molecules which have been proposed to play some role in the development of AMD are the proteins of the complement system. See for example U.S. published patent application numbers 20030017501, 20020102581, 20030149997, 20020015957, and 20030207309, and WO 03071927.

[008] The complement system consists of a group of globulins in the serum of humans (Hood, L. E. et al. 1984, *Immunology*, 2d Edition, The Benjamin/Cummings Publishing Co., Menlo Park, Calif., p. 339; See also, U.S. Pat. Nos. 6,087,120 and 5,808,109). Complement activation plays an important role in the mediation of immune and allergic reactions (Rapp, H. J. and Borsos, T., 1970, *Molecular Basis of Complement Action*, Appleton-Century-Crofts (Meredith), N.Y.). The activation of complement components leads to the generation of a group of factors, including

chemotactic peptides that mediate the inflammation associated with complement-dependent diseases. The activities mediated by activated complement proteins include lysis of target cells, chemotaxis, opsonization, stimulation of vascular and other smooth muscle cells, degranulation of mast cells, increased permeability of small blood vessels, directed migration of leukocytes, and activation of B lymphocytes, macrophages and neutrophils (Eisen, H. N., 1974, Immunology, Harper & Row, Publishers, Inc., Hagerstown, Md., p. 512).

[0009] The "alternative pathway" of the complement system provides natural, non-immune defense against microbial infections. In addition, this pathway amplifies antibody-antigen reactions. Alternative pathway recognition occurs in the presence of C3b and an activating substance such as bacterial lipoprotein, surfaces of certain parasites, yeasts, viruses and other foreign body surfaces, such as biomaterials. The alternative pathway of the complement system involves the recognition of certain polysaccharides (e.g., on microbial surface) and is activated by the presence of a specific substrate called C3bB, a complex of complement proteins. See, e.g., Cooper, *Adv Immunol*, 37(-HD-):151-216, 1985; Fearon & Austen, *J. Exp. Med.* 146: 22-33, 1977; Pangburn et al., 266: 16847-53, 1991; Matsushita et al., *Microbiol Immunol*, 40(12):887-93, 1996; and Turner et al., *Res Immunol*, 147(2):110-5, 1996. The main alternative pathway components are designated factor B, factor D, Properdin, factor H and factor I.

[0010] In recent years, a significant number of mutations have been identified in the gene encoding human Factor H, known as HF1 (Rodriguez Cordoba et al., *Molec. Immunol.* 41: 355-367 (2004)), which has revealed an association with two different renal diseases, glomerulonephritis and atypical hemolytic uremic syndrome (aHUS). Factor H deficiencies in mouse and humans have been described, including mutations that result in truncations or amino acid substitutions that impair secretion of factor H into the circulation (Ault et al., *J. Biol. Chem.* 272: 25168-75 (1997); Sanchez-Corral et al., *Immunogenetics* 51:366-399 (2000); Hegasy et al., *Immunogenetics* 55:462-71 (2003). Lack of factor H in plasma causes uncontrolled activation of the alternative pathway, with consumption of C3 and often other terminal complement components (Thompson et al., *Clin. Exp. Immunol.* 46: 110-119 (1981); Ault et al. 1997).

[0011] No gene(s) has yet been identified that causes a significant proportion of AMD. Moreover, no major molecular pathways involved in the etiology of this disease have been elucidated. It would be desirable to identify such genes and methods of determining which individuals are at increased risk for developing AMD.

SUMMARY OF THE INVENTION

[0012] The present invention provides novel methods for screening individuals for increased susceptibility to, or current affliction with, a disease or disorder associated with a variance (e.g., mutation or polymorphism) in the gene encoding complement factor H (*CFH*). Such complement factor H-associated diseases or disorders include eye diseases and disorders, including age-related macular degeneration (AMD), optic nerve disorders and cardiovascular disease. Preferably, the disease or disorder is AMD.

[0013] In one embodiment, the methods comprise obtaining a biological sample from an individual and screening for variations (e.g. changes) in the human *CFH* gene or gene product relative to a control group (e.g. wildtype, positive and/or negative control group). The presence of a variance (e.g. a change, mutation, polymorphism, or SNP) in the human *CFH* gene or CFH protein in the biological sample, as compared to the control group, indicates susceptibility to, or current affliction with, a CFH-associated disease or disorder. In a preferred embodiment the CFH-associated disease or disorder is AMD.

[0014] We have discovered that polymorphisms in the human gene encoding complement factor H, *CFH*, are highly associated with AMD. For example, possession of at least one histidine (a change from tyrosine) at amino acid position 402 of SEQ ID NO: 2 increases the risk of AMD 2.7-fold and may account for 50% of the attributable risk of AMD. Thus, in one embodiment, the AMD-predisposing allele is a polymorphism or mutation within the coding portion of the *CFH* gene. In one preferred embodiment, the AMD-predisposing allele is a polymorphism or mutation which encodes an amino residue located within a short consensus repeat (SCR) of CFH; one preferred SCR is SCR7. In one particularly preferred embodiment, the

AMD-predisposing allele of the *CFH* gene is a change from tyrosine at amino acid 402 of *CFH* (SEQ ID NO:2). Even more preferably, the polymorphism changes a tyrosine at position 402 to a histidine.

[0015] The presence or absence of the polymorphisms (also known as AMD-predisposing alleles) can be determined by any means known in the art. Preferably, one screens the *CFH* gene for any changes in the nucleic acid sequence. Preferably, the nucleotide to be screened is at position 1277 of SEQ ID NO: 1. A change at this position from a thymine to a cytosine indicates susceptibility to, or current affliction with, AMD. Alternatively, one can screen complement factor H protein for any changes in the amino acid sequence. Here, a change at amino acid number 402 of SEQ ID NO: 2 (e.g. from a Tyrosine to a Histidine) is indicative of susceptibility to, or current affliction with, AMD.

[0016] In one embodiment, a probe is used to screen for variances (e.g., mutations and/or polymorphisms) in the human *CFH* gene. Variances in the human *CFH* gene may also be determined via sequence analysis, such as, for example, amplification assays such PCR, qPCR, rtPCR, or gene arrays. Alternatively, variances in the human *CFH* gene may also be detected in the *CFH* gene product (e.g. mRNA or protein). Probes may be useful to screen for variances in the human *CFH* protein.

[0017] In one embodiment of the present invention, a biological sample from a patient with or at risk for developing ocular or cardiovascular disease and/or disorders is analyzed. A variance in the human *CFH* gene is indicative of the presence of or the possibility of future affliction with, a complement factor H-associated diseases or disorders including eye diseases and disorders, including age-related macular degeneration (AMD), optic nerve disorders and cardiovascular disease. Preferably, the variance a change from tyrosine at amino acid 402 of *CFH* to a histidine.

[0018] The detection of the presence or absence of at least one nucleic acid variance can be determined by amplifying a segment of nucleic acid encoding human *CFH*. The segment to be amplified is 1000 nucleotides in length, preferably, 500 nucleotides in length, and most preferably 100 nucleotides in length or less. The segment to be amplified can include a plurality of variances.

[0019] In another embodiment, the presence or absence of a variance in the human *CFH* gene can be detected by analyzing the gene product (e.g., protein). In one embodiment, a probe that specifically binds to a variant CFH is utilized. In a preferred embodiment, the probe is an antibody that preferentially binds to a variant CFH. The presence of a variant CFH predicts the likelihood of susceptibility to a complement factor H-associated diseases or disorder. Alternatively, the probe may be an antibody fragment, chimeric antibody, humanized antibody or an aptamer.

[0020] The present invention further provides a novel method for treating a patient affected with or at risk for developing an ocular disease or disorder, such as, for example, AMD. The method involves determining whether the human *CFH* gene of a patient contains at least one nucleic acid variance. Preferably, the variance is a change from tyrosine at amino acid 402 of CFH to a histidine. The presence of such a variance indicates that a CFH targeted treatment will be effective. If the variance is present, a suitable treatment plan may be initiated.

[0021] Suitable treatments plans are known to those of skill in the art and include, for example, the administration of angiogenesis inhibitors, VEGF inhibitors and the like. Preferably, a VEGF inhibitor is administered to a patient identified with a variance in CFH gene or gene product. Preferably, the VEGF inhibitor is ranibizumab (Lucentis™), a humanized antibody fragment designed to bind to and inhibit the activity of VEGF. In another embodiment, after diagnosis of a mutation or polymorphism in the human *CFH* gene, a photodynamic laser therapy (e.g. Visudyne®) and/or pegaptanib sodium (Macugen®) treatment is initiated. Other suitable treatment plans are known to those of skill in the art and are encompassed herein. In a preferred embodiment, treatment is initiated before the onset of symptoms (e.g. immediately after diagnosis of a mutation and/or polymorphism in CFH gene) and thus the dosages used in the treatment may be reduced.

BRIEF DESCRIPTION OF THE DRAWINGS

[0022] Figure 1 shows that the regulation of complement activation (RCA) locus located within chromosome 1q31.3 includes the gene for complement factor H

(*CFH*), 5 related genes derived from *CFH* through ancestral duplications, and the gene for factor 13B (*F13B*). A megabase (Mb) scale of this region is provided at the top of the figure. SNPs genotyped across the RCA locus are shown along the bottom of the figure. The negative natural logarithm of the significance of allele association to AMD for each SNP is given in the graph (10). The 0.05 significance level is shown by the dotted line. Values greater than 15 on the y-axis correspond to *P*-values less than 10^{-7} .

[0023] Figure 2 shows pairwise linkage disequilibrium (LD) among 38 SNPs in and surrounding the RCA locus, spanning the region including the 5' upstream region of *CFH* (represented by the SNP rs3753394) and the proximal portion of *FRBZ1* (represented by the SNP rs10732295), a distance of 516 kb. LD was measured by the *D'* statistic using data from all subjects in the discovery sample (10). A *D'* value of 1 indicates complete linkage disequilibrium between two markers and a *D'* value of 0 indicates complete linkage equilibrium. Using the Haploview version 3.0 software, we divided the RCA locus into four haplotype blocks (29). *D'* values for all, or nearly all, pairwise comparisons within a haplotype block are at least 0.8 (black squares). The haplotype block structure is similar to that obtained by the HapMap Project for this region in Caucasians with the notable difference that blocks 2 and 3 in the our structure comprise one block in the HapMap report (10). The lone SNP (rs379370) between blocks 2 and 3 is a nscSNP in the *CFHL4* gene (Table 3) showing moderate LD (gray squares), modest LD (light gray squares), or low LD (white squares) with the SNPs in block 3.

[0024] Figure 3 shows that the ARMD1 locus spans 14 megabases (Mb) based on meiotic breakpoint mapping (Table 3, 19) and includes 46 genes arranged in 6 clusters. Short tandem repeat markers delineating and confirming the ARMD1 locus in linkage studies are provided underneath the Mb scale. The number of SNPs genotyped is provided under each cluster. Three simultaneous strategies were pursued for genotyping across the ARMD1 locus: common nscSNPs, exclusion of the Fibulin-6 candidate gene (*S19*), and gene-based SNPs at 8 kb to 25 kb density. After association of AMD to the regulation of complement activation locus (genes *CFH* through *F13B* in cluster 6) was identified, new SNP assays were not designed for

other regions of the genome. For this reason, no gene-based genotyping was performed in clusters 2 and 5. 236 SNPs are reported herein and in Table 4.

[0025] Figure 4 shows the nucleic acid sequence of the gene, *CFH*, encoding human complement factor H (SEQ ID NO:1).

[0026] Figure 5 shows the amino acid sequence of human complement factor H (SEQ ID NO:2).

[0027] Figure 6 shows the alignment of SCR7 regions in complement factor H from four species, including human.

[0028] Figure 7 shows the nucleic acid sequence of the gene, *CFH*, encoding human complement factor H (SEQ ID NO:9; Genbank Accession No. NM000186). By historical convention, the Genbank sequence is listed with a C at position 1277 that codes for the histidine variant the present invention associates with AMD. Figure 6 shows conservation of Tyr at position 402 in the amino acid sequence. The histidine variant is the minor allele in the population.

[0029] Figure 8 shows the amino acid sequence of human complement factor H (SEQ ID NO:10; Genbank Accession No. NP000177). As described above, by historical convention the Genbank sequence is listed with a Histidine at position 402. Figure 6 shows conservation of Tyr at position 402. This histidine variant is the minor allele in the population.

DETAILED DESCRIPTION OF THE INVENTION

[0030] We have discovered that variances (e.g. changes such as mutations and/or polymorphisms) in the human gene encoding complement factor H, *CFH*, from the wildtype sequence are highly associated with age-related macular degeneration (AMD). Accordingly, the present invention provides novel methods for screening for individuals with increased susceptibility to, or current affliction with, a disease or disorder associated with a mutation or polymorphism in the gene encoding complement factor H in comparison to the population at large. Complement factor H-associated diseases include eye diseases, including age-related macular degeneration (AMD), optic nerve disorders and cardiovascular disease. For example, using two

independent case-control populations, significant association ($P = 4.95 \times 10^{-10}$) with AMD was identified within the regulation of complement activation locus, and centered over a Tyr402His protein polymorphism in the gene encoding complement factor H. As described in detail below, possession of at least one allele encoding histidine at amino acid 402 increased the risk of AMD 2.7-fold, and accounts for 50% of the attributable risk of AMD.

[0031] A single nucleotide polymorphism (SNP) in the gene encoding human complement factor H, in which a cytosine is present at position 1277 in SEQ ID NO: 1 (as opposed to the wildtype (e.g. negative control) shown in FIG. 4, where a thymine is present at position 1277), that codes for a histidine instead of a tyrosine at amino acid 402 of CFH is responsible for increased susceptibility to AMD. The presence of such C-allele in the CFH gene in an individual is predictive of increased susceptibility to AMD, whereas a T allele is protective. This polymorphism is sometimes referred to as "T1277C" or "Y402H". A single histidine allele (heterozygous) confers an increased risk of AMD, whereas two histidine alleles (homozygous) confers an even greater predictability of risk. The mutation is in a region of CFH that binds to both heparin and C-reactive protein. Furthermore, the presence of such a mutation may confirm the presence of AMD, for example at early stages of disease when symptoms may not be evident.

[0032] The screening methods of the present invention predict susceptibility to atrophic, exudative, geographic and neovascular AMD. In a preferred embodiment, the presence of the T1277C polymorphism is predictive of future onset of exudative AMD. Furthermore, the methods of the present invention may be combined with other diagnostic methods known to those of skill in the art or those to be discovered subsequently.

[0033] The present invention also provides novel methods of screening individuals to determine if they have an increased susceptibility to cardiovascular disorders in comparison to the population at large, by screening for mutations and/or polymorphisms in the gene encoding human complement factor H. Risk factors shared by cardiovascular disease and AMD include a high fat diet, lack of exercise, diet, elevated CRP levels and obesity. In addition, there is increased cardiovascular

mortality in patients with advanced AMD. See AREDS Report No. 13, Arch. Ophthalmol. 122: 716-726 (2004). The presence of the T1277C polymorphism indicates increased susceptibility to cardiovascular disease, including, but not limited to, myocardial infarction, ischaemic stroke, and venous thromboembolism.

[0034] In one embodiment, the patient population screened is Caucasian. In a preferred embodiment, the patient population is Caucasian and at least age 45, more preferably age 50, even more preferably age 55, 60, 65, 70, etc. Any race and age may be screened and individuals may be chosen by their physician according to the presence of risk factors such as, for example, age, ethnicity, smoking habits, hypertension, obesity, familial history of AMD and diet. Other risk factors are known to those of skill in the art.

[0035]—In one embodiment, the present methods involve using a probe to screen for variances (e.g. changes, mutations, polymorphisms, SNPs) in the human *CFH* gene or gene products, and its variants from alternative splicing or other means, relative to a control group (e.g. wildtype sequence).

[0036] According to the present invention, a "baseline" or "control" or "control group" can include a normal or negative control and/or a disease or positive control, against which a test sample can be compared. Therefore, it can be determined, based on the control, whether a sample to be evaluated for mutations and/or polymorphisms in the human *CFH* gene has a measurable difference or substantially no difference, as compared to the control group. In one aspect, the baseline control is a negative control. The negative control has a *CFH* gene as expected in the sample of a normal (e.g., healthy, negative control) individual. Therefore, the term "negative control" used herein typically refers to a population of individuals whose *CFH* sequence is similar to SEQ ID NO. 1, namely, a T at position 1277, which is believed to be normal (i.e., not having or developing susceptibility to ocular diseases or disorders). In some embodiments of the invention, it may also be useful to compare the gene expression in a test sample to a baseline that has previously been established from a patient or population of patients having susceptibility to ocular disorders. Such a baseline level, also referred to herein as a "positive control", refers to a *CFH* gene expression established from one or preferably a population of individuals who has been

positively diagnosed with or having susceptibility to ocular disorders and whom have CFH sequence similar to SEQ ID NO: 9 (e.g. a c instead of a t at position 1277).

Mutations and/or Polymorphisms in CFH

[0037] The present invention provides methods for determining changes at specific locations in DNA and/or protein sequence, typically referred to as polymorphisms or sometimes mutations, sometimes referred to as SNPs or polymorphic alleles, associated with AMD, nucleic acid molecules containing polymorphisms, methods and reagents for the detection of the changes in the wildtype sequence of *CFH*, uses of these polymorphisms for the development of detection reagents, and assays or kits that utilize such reagents. The AMD-associated polymorphisms disclosed herein are useful for diagnosing, screening for, and evaluating predisposition and prognosis to AMD and related pathologies in humans. The AMD-associated polymorphisms are also useful in detecting disease or disorder that is already present. A treatment regime can then be implemented. For example, administration of an anti-angiogenic agent. Preferably, one begins treatment as soon as possible. This is particularly important in early stages when it may be difficult to diagnose disease or disorder. Furthermore, such CFH proteins containing mutations or variations are useful targets for the development of therapeutic agents.

[0038] *CFH* encodes complement factor H, a single polypeptide chain plasma glycoprotein of 155 kDa. The secreted form of the protein is composed of 20 repetitive units of 60 amino acids, named short consensus repeats (SCR) arranged in a continuous fashion like a string of 20 beads (Ripoche et al., *Biochem. J.* 249: 593-602 (1988)). The SCRs have a typical framework of highly conserved residues including four cysteines, two prolines, one tryptophan, and several other partially conserved glycines and hydrophobic residues. See Rodriguez de Cordoba et al., *Molec. Immuno.* 41:355-67 (2004). The Tyr402His polymorphism is located within SCR7, which contains the overlapping binding sites for heparin, C-reactive protein, and M-protein.

[0039] Re-interpretation of existing literature strongly suggests that the histidine variant of CFH is inactive in biologically important ways compared to the tyrosine variant of CFH. This prior work is consistent with reduced biological activity for the histidine variant of CFH. Two populations of CFH referred to as ϕ_1 and ϕ_2 can be isolated based on hydrophobic affinity chromatography (J. Ripoché, A. Al Salihi, J. Rousseaux, M. Fontaine, *Biochem J* 221, 89 (Jul 1, 1984)). Both populations have identical polypeptide chain length and interact equally well with C3b, but ϕ_2 is bound by phenyl-Sepharose while ϕ_1 is slightly retarded on the column (Ripoché et al., 1984). Only the ϕ_2 population induced aggregation of sheep red blood cells coated with complement components, bound specifically to a human B lymphoblastoid cell line, and induced secretion of lymphocyte-activating factor by human monocytes leading to the suggestion that ϕ_2 might represent an activated form of CFH (Ripoché et al., 1984; J. Ripoché et al., *Biochem J* 253, 475 (Jul 15, 1988); D. Iferroudjène, M. T. Schouff, C. Lemerrier, D. Gilbert, M. Fontaine, *Eur J Immunol* 21, 967 (Apr, 1991). Additional experiments showed differing immunoreactivity to monoclonal antibodies and conversion of the chromatographic properties of ϕ_2 to those of ϕ_1 by iodination of tyrosine residues, demonstrating that a change at one or more tyrosine residues accounted for the difference between ϕ_1 and ϕ_2 (Ripoché et al. 1988; C. Lemerrier, O. Duval, J. Ripoché, R. B. Sim, M. Fontaine, *Complement Inflamm* 8, 181 (1991)). Most individual sera had equal proportions of ϕ_1 and ϕ_2 , but some individuals had only one population consistent with a co-dominant protein polymorphism (Lemerrier et al.). These observations suggest that ϕ_1 represents the histidine variant and ϕ_2 the tyrosine variant. We found that the replacement of tyrosine with histidine at amino acid 402 of CFH, results in decreased inhibition of the alternative complement pathway in the outer retina and choroid. A lifetime of abnormal regulation of inflammation gives rise to the formation of subretinal deposits and eventually AMD. This hypothesis is further supported by the observation of drusen with terminal complement deposition indistinguishable from AMD in eyes from patients with a kidney disease (membranoproliferative glomerulonephritis type II) that can be caused by mutations in CFH (R. F. Mullins, N. Aptsiauri, G. S.

Hageman, *Eye* 15, 390 (Jun, 2001); M. A. Dragon-Durey *et al.*, *J Am Soc Nephrol* 15, 787 (Mar, 2004)).

[0040] In one embodiment, the AMD-predisposing allele is a polymorphism or mutation within the coding portion of the *CFH* gene (SEQ ID NO:1). In one preferred embodiment, the AMD-predisposing allele is a polymorphism or mutation which encodes an amino acid residue located within a short consensus repeat (SCR) of CFH; one preferred SCR is SCR7, as shown in Figure 6. In one particularly preferred embodiment, the AMD-predisposing allele of the *CFH* gene is a change from tyrosine at amino acid 402 of CFH. Even more preferably, the polymorphism changes a tyrosine at position 402 to a histidine.

[0041] In one embodiment, one can also look for such changes in the corresponding complement factor H gene product (SEQ ID NO:2). This can be readily done by standard means such as antibodies that recognize specific epitopes. In one embodiment one can use an antibody to the C-terminus to recognize mutations resulting in truncations of the protein or changes in its level of expression. One can also generate antibodies that will only recognize specific amino acid sequences. For example, antibodies that recognize the polymorphic protein (or protein fragment) of SEQ ID NO: 10 and does not recognize the wildtype protein (or protein fragment) of SEQ ID NO: 2 are encompassed. Antibodies and antibody fragments, polyclonal or monoclonal, can be purchased from a variety of commercial suppliers, or may be manufactured using well-known methods, e. g., as described in Harlow *et al.*, *Antibodies: A Laboratory Manual*, 2nd Ed; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (1988).

[0042] The term "antibody" is meant to be an immunoglobulin protein that is capable of binding an antigen. Antibody as used herein is meant to include antibody fragments, e.g. F(ab')₂, Fab', Fab, capable of binding the antigen or antigenic fragment of interest. Preferably, the antibody is diagnostic in that it discriminatively binds to either the wildtype or the AMD-predisposing allele of CFH described herein.

[0043] An AMD-predisposing allele may be located within a coding region of CFH or a non-coding region of CFH. Non-coding regions include, for example, intron sequences as well as 5' and 3' untranslated sequences. In one preferred

embodiment, the AMD-predisposing allele is located within a portion of the CFH gene which encodes SCR7. Changes of interest in a non-coding region include modifications of the nucleic acid such as methylation.

[0044] Another embodiment of the invention provides methods for identifying novel polymorphisms in the human CFH gene which are associated with AMD. The strength of the association between a polymorphic allele and AMD can be characterized by a particular odds ratio such as an odds ratio of at least 2 with a lower 95% confidence interval limit of greater than 1. Such an odds ratio can be, for example, at least 3.0, 4.0, 5.0, 6.0, 7.0, or 8.0 or greater with a lower 95% confidence interval limit of greater than 1. In one embodiment, the predisposing polymorphic allele is associated with AMD with an odds ratio of at least 2 and a lower 95% confidence limit greater than 1. Methods for determining an odds ratio are well known in the art (see, for example, Schlesselman et al., Case Control Studies: Design, Conduct and Analysis Oxford University Press, New York (1982)).

[0045] In one embodiment, an AMD-predisposing allele is associated with the AMD with a p value of equal to or less than 0.05. In other embodiments, an AMD-predisposing allele is associated with AMD with a p value of equal to or less than 0.01. As used herein, the term "p value" is synonymous with "probability value." As is well known in the art, the expected p value for the association between a random allele and disease is 1.00. A p value of less than about 0.05 indicates that the allele and disease do not appear together by chance but are influenced by positive factors. Generally, the statistical threshold for significance of linkage has been set at a level of allele sharing for which false positives would occur once in twenty genome scans ($p=0.05$). In particular embodiments, a AMD-predisposing allele is associated with AMD with a p value of equal to or less than 0.1, 0.05, 0.04, 0.03, 0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002 or 0.001, or with a p value of less than 0.00095, 0.0009, 0.00085, 0.0008 or 0.0005. It is recognized that, in some cases, p values may need to be corrected, for example, to account for factors such as sample size (number of families), genetic heterogeneity, clinical heterogeneity, or analytical approach (parametric or nonparametric method).

Detection of Mutations or Polymorphisms in CFH

[0046] According to the present invention, any approach that detects mutations or polymorphisms in a gene can be used, including but not limited to single-strand conformational polymorphism (SSCP) analysis (Orita et al. (1989) Proc. Natl. Acad. Sci. USA 86:2766-2770), heteroduplex analysis (Prior et al. (1995) Hum. Mutat. 5:263-268), oligonucleotide ligation (Nickerson et al. (1990) Proc. Natl. Acad. Sci. USA 87:8923-8927) and hybridization assays (Conner et al. (1983) Proc. Natl. Acad. Sci. USA 80:278-282). Traditional Taq polymerase PCR-based strategies, such as PCR-RFLP, allele-specific amplification (ASA) (Ruano and Kidd (1989) Nucleic Acids Res. 17:8392), single-molecule dilution (SMD) (Ruano et al. (1990) Proc. Natl. Acad. Sci. USA 87:6296-6300), and coupled amplification and sequencing (CAS) (Ruano and Kidd (1991) Nucleic Acids Res. 19:6877-6882), are easily performed and highly sensitive methods to determine haplotypes of the present invention (Michalatos-Beloin et al. (1996) Nucleic Acids Res. 24:4841-4843; Barnes (1994) Proc. Natl. Acad. Sci. USA 91:5695-5699; Ruano and Kidd (1991) Nucleic Acids Res. 19:6877-6882).

[0047] In one embodiment, a long-range PCR (LR-PCR) is used to detect mutations or polymorphisms of the present invention. LR-PCR products are genotyped for mutations or polymorphisms using any genotyping methods known to one skilled in the art, and haplotypes inferred using mathematical approaches (e.g., Clark's algorithm (Clark (1990) Mol. Biol. Evol. 7:111-122).

[0048] For example, methods including complementary DNA (cDNA) arrays (Shalon et al., Genome Research 6(7):639-45, 1996; Bernard et al., Nucleic Acids Research 24(8):1435-42, 1996), solid-phase mini-sequencing technique (U.S. Patent No. 6,013,431, Suomalainen et al. Mol. Biotechnol. Jun;15(2):123-31, 2000), ion-pair high-performance liquid chromatography (Doris et al. J. Chromatogr. A May 8;806(1):47-60, 1998), and 5' nuclease assay or real-time RT-PCR (Holland et al. Proc Natl Acad Sci USA 88: 7276-7280, 1991), or primer extension methods described in the U.S. Patent No. 6,355,433, can be used.

[0049] In one embodiment, the primer extension reaction and analysis is performed using PYROSEQUENCING™ (Uppsala, Sweden) which essentially is sequencing by synthesis. A sequencing primer, designed directly next to the nucleic acid differing between the disease-causing mutation and the normal allele or the different SNP alleles is first hybridized to a single stranded, PCR amplified DNA template from the individual, and incubated with the enzymes, DNA polymerase, ATP sulfurylase, luciferase and apyrase, and the substrates, adenosine 5' phosphosulfate (APS) and luciferin. One of four deoxynucleotide triphosphates (dNTP), for example, corresponding to the nucleotide present in the mutation or polymorphism, is then added to the reaction. DNA polymerase catalyzes the incorporation of the dNTP into the standard DNA strand. Each incorporation event is accompanied by release of pyrophosphate (PPi) in a quantity equimolar to the amount of incorporated nucleotide. Consequently, ATP sulfurylase converts PPi to ATP in the presence of adenosine 5' phosphosulfate. This ATP drives the luciferase-mediated conversion of luciferin to oxyluciferin that generates visible light in amounts that are proportional to the amount of ATP. The light produced in the luciferase-catalyzed reaction is detected by a charge coupled device (CCD) camera and seen as a peak in a PYROGRAM™. Each light signal is proportional to the number of nucleotides incorporated and allows a clear determination of the presence or absence of, for example, the mutation or polymorphism. Thereafter, apyrase, a nucleotide degrading enzyme, continuously degrades unincorporated dNTPs and excess ATP. When degradation is complete, another dNTP is added which corresponds to the dNTP present in for example the selected SNP. Addition of dNTPs is performed one at a time. Deoxyadenosine alfa-thio triphosphate (dATPαS) is used as a substitute for the natural deoxyadenosine triphosphate (dATP) since it is efficiently used by the DNA polymerase, but not recognized by the luciferase. For detailed information about reaction conditions for the PYROSEQUENCING, see, e.g. U.S. Patent No. 6,210,891, which is herein incorporated by reference in its entirety.

[0050] Another example of the methods useful for detecting mutations or polymorphisms is real time PCR. All real-time PCR systems rely upon the detection

and quantification of a fluorescent reporter, the signal of which increases in direct proportion to the amount of PCR product in a reaction. Examples of real-time PCR method useful according to the present invention include, TaqMan® and molecular beacons, both of which are hybridization probes relying on fluorescence resonance energy transfer (FRET) for quantitation. TaqMan Probes are oligonucleotides that contain a fluorescent dye, typically on the 5' base, and a quenching dye, typically located on the 3' base. When irradiated, the excited fluorescent dye transfers energy to the nearby quenching dye molecule rather than fluorescing, resulting in a nonfluorescent substrate. TaqMan probes are designed to hybridize to an internal region of a PCR product (ABI 7700 (TaqMan™), Applied BioSystems, Foster City, CA). Accordingly, two different primers, one hybridizing to the mutation or polymorphism and the other to the corresponding wildtype allele, are designed. The primers are consequently allowed to hybridize to the corresponding nucleic acids in the real time PCR reaction. During PCR, when the polymerase replicates a template on which a TaqMan probe is bound, the 5' exonuclease activity of the polymerase cleaves the probe. Consequently, this separates the fluorescent and quenching dyes and FRET no longer occurs. Fluorescence increases in each cycle, proportional to the rate of probe cleavage.

[0051] Molecular beacons also contain fluorescent and quenching dyes, but FRET only occurs when the quenching dye is directly adjacent to the fluorescent dye. Molecular beacons are designed to adopt a hairpin structure while free in solution, bringing the fluorescent dye and quencher in close proximity. Therefore, for example, two different molecular beacons are designed, one recognizing the mutation or polymorphism and the other the corresponding wildtype allele. When the molecular beacons hybridize to the nucleic acids, the fluorescent dye and quencher are separated, FRET does not occur, and the fluorescent dye emits light upon irradiation. Unlike TaqMan probes, molecular beacons are designed to remain intact during the amplification reaction, and must rebind to target in every cycle for signal measurement. TaqMan probes and molecular beacons allow multiple DNA species to be measured in the same sample (multiplex PCR), since fluorescent dyes with

different emission spectra may be attached to the different probes, e.g. different dyes are used in making the probes for different disease-causing and SNP alleles.

Multiplex PCR also allows internal controls to be co-amplified and permits allele discrimination in single-tube assays. (Ambion Inc, Austin, TX, TechNotes 8(1) - February 2001, Real-time PCR goes prime time).

[0052] Yet another method useful according to the present invention for detecting a mutation or polymorphism is solid-phase mini-sequencing (Hultman, et al., 1988, Nucl. Acid. Res., 17, 4937-4946; Syvanen et al., 1990, Genomics, 8, 684-692). In the original reports, the incorporation of a radiolabeled nucleotide was measured and used for analysis of the three-allelic polymorphism of the human apolipoprotein E gene. The method of detection of the variable nucleotide(s) is based on primer extension and incorporation of detectable nucleoside triphosphates in the detection step. By selecting the detection step primers from the region immediately adjacent to the variable nucleotide, this variation can be detected after incorporation of as few as one nucleoside triphosphate. Labelled nucleoside triphosphates matching the variable nucleotide are added and the incorporation of a label into the detection step primer is measured. The detection step primer is annealed to the copies of the target nucleic acid and a solution containing one or more nucleoside triphosphates including at least one labeled or modified nucleoside triphosphate, is added together with a polymerizing agent in conditions favoring primer extension. Either labeled deoxyribonucleoside triphosphates (dNTPs) or chain terminating dideoxyribonucleoside triphosphates (ddNTPs) can be used. The solid-phase mini-sequencing method is described in detail, for example, in the U.S. Patent No. 6,013,431 and in Wartiovaara and Syvanen, Quantitative analysis of human DNA sequences by PCR and solid-phase minisequencing, Mol Biotechnol 2000 Jun; 15(2):123-131.

[0053] Another method to detect mutations or polymorphisms is by using fluorescence tagged dNTP/ddNTPs. In addition to use of the fluorescent label in the solid phase mini-sequencing method, a standard nucleic acid sequencing gel can be

used to detect the fluorescent label incorporated into the PCR amplification product. A sequencing primer is designed to anneal next to the base differentiating the disease-causing and normal allele or the selected SNP alleles. A primer extension reaction is performed using chain terminating dideoxynucleoside triphosphates (ddNTPs) labeled with a fluorescent dye, one label attached to the ddNTP to be added to the standard nucleic acid and another to the ddNTP to be added to the target nucleic acid.

[0054] Alternatively, an INVADER[®] assay can be used (Third Wave Technologies, Inc (Madison, WI)). This assay is generally based upon a structure-specific nuclease activity of a variety of enzymes, which are used to cleave a target-dependent cleavage structure, thereby indicating the presence of specific nucleic acid sequences or specific variations thereof in a sample (see, e.g. U.S. Patent No. 6,458,535). For example, an INVADER[®] operating system (OS), provides a method for detecting and quantifying DNA and RNA. The INVADER[®] OS is based on a "perfect match" enzyme-substrate reaction. The INVADER[®] OS uses proprietary CLEAVASE[®] enzymes (Third Wave Technologies, Inc (Madison, WI)), which recognize and cut only the specific structure formed during the INVADER[®] process which structure differs between the different alleles selected for detection, i.e. the disease-causing allele and the normal allele as well as between the different selected SNPs. Unlike the PCR-based methods, the INVADER[®] OS relies on linear amplification of the signal generated by the INVADER[®] process, rather than on exponential amplification of the target.

[0055] In the INVADER[®] process, two short DNA probes hybridize to the target to form a structure recognized by the CLEAVASE[®] enzyme. The enzyme then cuts one of the probes to release a short DNA "flap." Each released flap binds to a fluorescently-labeled probe and forms another cleavage structure. When the CLEAVASE[®] enzyme cuts the labeled probe, the probe emits a detectable fluorescence signal.

[0056] Mutations or polymorphisms may also be detected using allele-specific hybridization followed by a MALDI-TOF-MS detection of the different hybridization

products. In the preferred embodiment, the detection of the enhanced or amplified nucleic acids representing the different alleles is performed using matrix-assisted laser desorption ionization/time-of-flight (MALDI-TOF) mass spectrometric (MS) analysis described in the Examples below. This method differentiates the alleles based on their different mass and can be applied to analyze the products from the various above-described primer-extension methods or the INVADER[®] process.

[0057] In one embodiment, a haplotyping method useful according to the present invention is a physical separation of alleles by cloning, followed by sequencing. Other methods of haplotyping, useful according to the present invention include, but are not limited to monoallelic mutation analysis (MAMA) (Papadopoulos et al. (1995) *Nature Genet.* 11:99-102) and carbon nanotube probes (Woolley et al. (2000) *Nature Biotech.* 18:760-763). U.S. Patent Application No. US 2002/0081598 also discloses a useful haplotyping method which involves the use of PCR amplification.

[0058] Computational algorithms such as expectation-maximization (EM), subtraction and PHASE are useful methods for statistical estimation of haplotypes (see, e.g., Clark, A.G. Inference of haplotypes from PCR-amplified samples of diploid populations. *Mol Biol Evol* 7, 111-22. (1990); Stephens, M., Smith, N.J. & Donnelly, P. A new statistical method for haplotype reconstruction from population data. *Am J Hum Genet* 68, 978-89. (2001); Templeton, A.R., Sing, C.F., Kessling, A. & Humphries, S. A cladistic analysis of phenotype associations with haplotypes inferred from restriction endonuclease mapping. II. The analysis of natural populations. *Genetics* 120, 1145-54. (1988)).

Genotyping CFH Alleles

[0059] According to one aspect of the present invention, a method for determining whether a human is homozygous for a polymorphism, heterozygous for a polymorphism, or lacking the polymorphism altogether (i.e. homozygous wildtype) is encompassed. For example, for the Tyr402His polymorphism, a method for determining the C-allele, heterozygous for the C- and T-alleles, or homozygous for

the T-allele of the human CFH gene is provided. Substantially any method of detecting an allele of the CFH gene, such as hybridization, amplification, restriction enzyme digestion, and sequencing methods, can be used.

[0060] In one embodiment, a haplotyping method useful according to the present invention is a physical separation of alleles by cloning, followed by sequencing. Other methods of haplotyping, useful according to the present invention include, but are not limited to monoallelic mutation analysis (MAMA) (Papadopoulos et al. (1995) *Nature Genet.* 11:99-102) and carbon nanotube probes (Woolley et al. (2000) *Nature Biotech.* 18:760-763). U.S. Patent Application No. US 2002/0081598 also discloses a useful haplotyping method which involves the use of PCR amplification.

[0061] Computational algorithms such as expectation-maximization (EM), subtraction and PHASE are useful methods for statistical estimation of haplotypes (see, e.g., Clark, A.G. Inference of haplotypes from PCR-amplified samples of diploid populations. *Mol Biol Evol* 7, 111-22. (1990); Stephens, M., Smith, N.J. & Donnelly, P. A new statistical method for haplotype reconstruction from population data. *Am J Hum Genet* 68, 978-89. (2001); Templeton, A.R., Sing, C.F., Kessling, A. & Humphries, S. A cladistic analysis of phenotype associations with haplotypes inferred from restriction endonuclease mapping. II. The analysis of natural populations. *Genetics* 120, 1145-54. (1988)).

[0062] In one embodiment, an allelic discrimination method for identifying the CFH genotype of a human can be used. The allelic discrimination method of the invention involves use of a first oligonucleotide probe which anneals with a target portion of the individual's genome. The target portion comprises a portion of the region of CFH gene to be screened, for example, including the nucleotide residue at position 1277 in SEQ ID NO: 1. Because the nucleotide residue at this position differs, for example at position in the C-allele and the T-allele, the first probe is completely complementary to only one of the two alleles. Alternatively, a second oligonucleotide probe can also be used which is completely complementary to the target portion of the other of the two alleles. The allelic discrimination method of the

invention also involves use of at least one, and preferably a pair of amplification primers for amplifying a reference region of the CFH gene of an individual. The reference region includes at least a portion of the human CFH, for example a portion including the nucleotide residue at position 1277 of the CFH gene in SEQ ID NO: 1.

[0063] Because the reference region and the target portion overlap by at least one base, preferably by at least about half the length of the target portion, and more preferably completely overlap, the enzyme (e.g. *Thermus aquaticus* {Taq} DNA polymerase) which catalyzes the amplification reaction and the first (or second) probe will collide. If the probe is not completely complementary to the target portion, it is more likely to dissociate from the target portion upon collision than if it is completely complementary. Therefore, unless the enzyme exhibits 5'→3' exonuclease activity, amplification ceases or is greatly inhibited.

[0064] If the enzyme which catalyzes the amplification reaction exhibits 5'→3' exonuclease activity (e.g. Taq DNA polymerase), then the enzyme will at least partially degrade the 5'-end of a probe with which it collides unless the probe dissociates from the target portion upon collision with the enzyme. As noted above, if the probe is not completely complementary to the target portion, it is much more likely to dissociate from the target portion upon collision than if it is completely complementary. If a detectable label is attached to a nucleotide residue at or near the 5'-end of the probe, release of the detectable label from the probe can be used as an indication that the enzyme and probe have collided and that the probe did not dissociate from the target portion. Thus, release of the detectable label from the probe upon amplification of the region indicates that the probe was completely complementary to the target portion. By selecting either or both of a probe completely complementary to the target portion of the polymorphism of the CFH gene and a probe completely complementary to the wildtype site at the target portion of the gene and assessing release of the label from the probe(s), the identity of the allele(s) can be ascertained.

[0065] The probe is preferably a DNA oligonucleotide having a length in the range from about 20 to about 40 nucleotide residues, preferably from about 20 to about 30 nucleotide residues, and more preferably having a length of about 25

nucleotide residues. In one embodiment, the probe is rendered incapable of extension by a PCR-catalyzing enzyme such as Taq polymerase, for example by having a fluorescent probe attached at one or both ends thereof. Although non-labeled oligonucleotide probes can be used in the kits and methods of the invention, the probes are preferably detectably labeled. Exemplary labels include radionuclides, light-absorbing chemical moieties (e.g. dyes), fluorescent moieties, and the like. Preferably, the label is a fluorescent moiety, such as 6-carboxyfluorescein (FAM), 6-carboxy-4,7,2',7'-tetrachlorofluorescein (TET), rhodamine, JOE (2,7-dimethoxy-4,5-dichloro-6-carboxyfluorescein), HEX (hexachloro-6-carboxyfluorescein), or VIC.

[0066] In a particularly preferred embodiment, the probe of the invention comprises both a fluorescent label and a fluorescence-quenching moiety such as 6-carboxy-N,N,N',N'-tetramethylrhodamine (TAMRA), or 4-(4'-dimethylaminophenylazo)benzoic acid (DABCYL). When the fluorescent label and the fluorescence-quenching moiety are attached to the same oligonucleotide and separated by no more than about 40 nucleotide residues, and preferably by no more than about 30 nucleotide residues, the fluorescent intensity of the fluorescent label is diminished. When one or both of the fluorescent label and the fluorescence-quenching moiety are separated from the oligonucleotide, the intensity of the fluorescent label is no longer diminished. Preferably, the probe of the invention has a fluorescent label attached at or near (i.e. within about 10 nucleotide residues of) one end of the probe and a fluorescence-quenching moiety attached at or near the other end. Degradation of the probe by a PCR-catalyzing enzyme releases at least one of the fluorescent label and the fluorescence-quenching moiety from the probe, thereby discontinuing fluorescence quenching and increasing the detectable intensity of the fluorescent labels. Thus, cleavage of the probe (which, as discussed above, is correlated with complete complementarity of the probe with the target portion) can be detected as an increase in fluorescence of the assay mixture.

[0067] If detectably different labels are used, more than one labeled probe can be used. For example, the assay mixture can contain a first probe which is completely complementary to the target portion of the polymorphism of the CFH gene and to which a first label is attached, and a second probe which is completely

complementary to the target portion of the wildtype allele. When two probes are used, the probes are detectably different from each other, having, for example, detectably different size, absorbance, excitation, or emission spectra, radiative emission properties, or the like. For example, a first probe can be completely complementary to the target portion of the polymorphism and have FAM and TAMRA attached at or near opposite ends thereof. The first probe can be used in the method of the invention together with a second probe which is completely complementary to the target portion of the wildtype allele and has TET and TAMRA attached at or near opposite ends thereof. Fluorescent enhancement of FAM (i.e. effected by cessation of fluorescence quenching upon degradation of the first probe by Taq polymerase) can be detected at one wavelength (e.g. 518 nanometers), and fluorescent enhancement of TET (i.e. effected by cessation of fluorescence quenching upon degradation of the second probe by Taq polymerase) can be detected at a different wavelength (e.g. 582 nanometers).

[0068] Ideally, the probe exhibits a melting temperature (T_m) within the range from about 60°C to 70°C, and more preferably in the range from 65°C to 67°C. Furthermore, because each probe is completely complementary to only one of the alleles of the CFH gene, each probe will necessarily have at least one nucleotide residue which is not complementary to the corresponding residue of the other allele. This non-complementary nucleotide residue of the probe is preferably located near the midsection of the probe (i.e. within about the central third of the probe sequence) and is preferably approximately equidistant from the ends of the probe. Thus, for example, the probe which is completely complementary to the polymorphic allele of the human CFH gene can, for example, be completely complementary to nucleotide residues surrounding position 1277 of the polymorphic allele, as defined by the positions of SEQ ID NO: 1. For example, because the C- and T-alleles differ at position 1277, this probe will have a mismatched base pair nine nucleotide residues from one end when it is annealed with the corresponding target portion of the T-allele.

[0069] By way of example, labeled probes having the sequences of SEQ ID NOs: 3-4 can be used, in conjunction with labeled probes having the sequences of SEQ ID NOs: 5 and 6 in order to determine the allelic content of an individual (e.g. to assess

whether the mammal comprises one or both of an C allele and a T allele of CFH at position 1277). For example, custom TaqMan SNP genotyping probes for each allele can be designed using Primer Express® v2.0 software (Applied Biosystems) using recommended guidelines. Successful discrimination of each allele can be verified using population control individuals. Genomic DNA (e.g. 20ng) can be amplified according to assay recommendations and genotyping analysis performed, as described in greater detail below.

[0070] The size of the reference portion which is amplified according to the allelic discrimination method of the invention is preferably not more than about 100 nucleotide residues. It is also preferred that the T_m for the amplified reference portion with the genomic DNA or fragment thereof be in the range from about 57°C to 61°C, where possible.

[0071] It is understood that binding of the probe(s) and primers and that amplification of the reference portion of the CFH gene according to the allelic discrimination method of the invention will be affected by, among other factors, the concentration of Mg⁺⁺ in the assay mixture, the annealing and extension temperatures, and the amplification cycle times. Optimization of these factors requires merely routine experimentation which are well known to skilled artisans.

[0072] Another allelic discrimination method suitable for use in the present invention employs "molecular beacons". Detailed description of this methodology can be found in Kostrikis et al., Science 1998;279:1228-1229, which is incorporated herein by reference.

[0073] The use of microarrays comprising a multiplicity of reference sequences is becoming increasingly common in the art. Accordingly, another aspect of the invention comprises a microarray having at least one oligonucleotide probe, as described above, appended thereon.

[0074] It is understood, however, that any method of ascertaining an allele of a gene can be used to assess the genotype of the CFH gene in a mammal. Thus, the invention includes known methods (both those described herein and those not explicitly described herein) and allelic discrimination methods which may be hereafter developed.

[0075] With reference to nucleic acids of the invention, the term "isolated nucleic acid" or "isolated polynucleotide" is sometimes used. This term, when applied to DNA, refers to a DNA molecule that is separated from sequences with which it is immediately contiguous (in the 5' and 3' directions) in the naturally occurring genome of the organism from which it originates. For example, the "isolated nucleic acid" may comprise a DNA or cDNA molecule inserted into a vector, such as a plasmid or virus vector, or integrated into the DNA of a prokaryote or eukaryote. With respect to RNA molecules of the invention, the term "isolated nucleic acid" primarily refers to an RNA molecule encoded by an isolated DNA molecule as defined above. Alternatively, the term may refer to an RNA molecule that has been sufficiently separated from RNA molecules with which it would be associated in its natural state (i.e., in cells or tissues), such that it exists in a "substantially pure" form. ---

[0076] The term "oligonucleotide," as used herein refers to primers and probes of the present invention, and is defined as a nucleic acid molecule comprised of two or more ribo- or deoxyribonucleotides, preferably more than three. The exact size of the oligonucleotide will depend on various factors and on the particular application and use of the oligonucleotide. The term "probe" as used herein refers to an oligonucleotide, polynucleotide or nucleic acid, either RNA or DNA, whether occurring naturally as in a purified restriction enzyme digest or produced synthetically, which is capable of annealing with or specifically hybridizing to a nucleic acid with sequences complementary to the probe. A probe may be either single-stranded or double-stranded. The exact length of the probe will depend upon many factors, including temperature, source of probe and the method used. For example, for diagnostic applications, depending on the complexity of the target sequence, the oligonucleotide probe typically contains 15-25 or more nucleotides, although it may contain fewer nucleotides. The probes herein are selected to be substantially complementary to different strands of a particular target nucleic acid sequence. This means that the probes must be sufficiently complementary so as to be able to "specifically hybridize" or anneal with their respective target strands. Therefore, the probe sequence need not reflect the exact complementary sequence of the target. For example, a non-complementary nucleotide fragment may be attached to

the 5' or 3' end of the probe, with the remainder of the probe sequence being complementary to the target strand. Alternatively, non-complementary bases or longer sequences can be interspersed into the probe, provided that the probe sequence has sufficient complementarity with the sequence of the target nucleic acid to anneal therewith specifically.

[0077] In the context of this invention, the term "probe" refers to a molecule which can detectably distinguish between target molecules differing in structure (e.g. nucleic acid or protein sequence). Detection can be accomplished in a variety of different ways depending on the type of probe used and the type of target molecule. Thus, for example, detection may be based on discrimination on detection of specific binding. Examples of such specific binding include antibody binding and nucleic acid, antibody binding to protein, nucleic acid binding to nucleic acid, or aptamer binding to protein or nucleic acid. Thus, for example, probes can include enzyme substrates, antibodies and antibody fragments, and preferably nucleic acid hybridization probes.

[0078] The term "specifically hybridize" refers to the association between two single-stranded nucleic acid molecules of sufficiently complementary sequence to permit such hybridization under pre-determined conditions generally used in the art (sometimes termed "substantially complementary"). In particular, the term refers to hybridization of an oligonucleotide with a substantially complementary sequence contained within a single-stranded DNA or RNA molecule of the invention, to the substantial exclusion of hybridization of the oligonucleotide with single-stranded nucleic acids of non-complementary sequence.

[0079] "Primer" as used herein refers to an oligonucleotide, either RNA or DNA, either single-stranded or double-stranded, either derived from a biological system, generated by restriction enzyme digestion, or produced synthetically which, when placed in the proper environment, is able to functionally act as an initiator of template-dependent nucleic acid synthesis. When presented with an appropriate nucleic acid template, suitable nucleoside triphosphate precursors of nucleic acids, a polymerase enzyme, suitable cofactors and conditions such as a suitable temperature and pH, the primer may be extended at its 3' terminus by the addition of nucleotides by the action of a polymerase or similar activity to yield a primer extension product.

The primer may vary in length depending on the particular conditions and requirement of the application. For example, in diagnostic applications, the oligonucleotide primer is typically 15-25 or more nucleotides in length. The primer must be of sufficient complementarity to the desired template to prime the synthesis of the desired extension product, that is, to be able to anneal with the desired template strand in a manner sufficient to provide the 3' hydroxyl moiety of the primer in appropriate juxtaposition for use in the initiation of synthesis by a polymerase or similar enzyme. It is not required that the primer sequence represent an exact complement of the desired template. For example, a non-complementary nucleotide sequence may be attached to the 5' end of an otherwise complementary primer. Alternatively, non-complementary bases may be interspersed within the oligonucleotide primer sequence, provided that the primer sequence has sufficient complementarity with the sequence of the desired template strand to functionally provide a template-primer complex for the synthesis of the extension product.

[0080] "Complementary" refers to the broad concept of sequence complementarity between regions of two nucleic acid strands or between two regions of the same nucleic acid strand. It is known that an adenine residue of a first nucleic acid region is capable of forming specific hydrogen bonds ("base pairing") with a residue of a second nucleic acid region which is anti-parallel to the first region if the residue is thymine or uracil. Similarly, it is known that a cytosine residue of a first nucleic acid strand is capable of base pairing with a residue of a second nucleic acid strand which is anti-parallel to the first strand if the residue is guanine. A first region of a nucleic acid is complementary to a second region of the same or a different nucleic acid if, when the two regions are arranged in an anti-parallel fashion, at least one nucleotide residue of the first region is capable of base pairing with a residue of the second region. Preferably, the first region comprises a first portion and the second region comprises a second portion, whereby, when the first and second portions are arranged in an anti-parallel fashion, at least about 50%, and preferably at least about 75%, at least about 90%, or at least about 95% of the nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion.

More preferably, all nucleotide residues of the first portion are capable of base pairing with nucleotide residues in the second portion.

[0081] As used herein, a first region of an oligonucleotide "flanks" a second region of the oligonucleotide if the two regions are adjacent one another or if the two regions are separated by no more than about 1000 nucleotide residues, and preferably no more than about 100 nucleotide residues.

[0082] A second set of primers is "nested" with respect to a first pair of primers if, after amplifying a nucleic acid using the first pair of primers, each of the second pair of primers anneals with the amplified nucleic acid, such that the amplified nucleic acid can be further amplified using the second pair of primers.

[0083] Nucleic acid molecules of the present invention may be prepared by two general methods: (1) Synthesis from appropriate nucleotide triphosphates, or (2) Isolation from biological sources. Both methods utilize protocols well known in the art.

[0084] The availability of nucleotide sequence information, such as a full length nucleic acid sequence having SEQ ID NO: 1, enables preparation of isolated nucleic acid molecules of the invention by oligonucleotide synthesis. Synthetic oligonucleotides may be prepared by the phosphoramidite method employed in the Applied Biosystems 38A DNA Synthesizer or similar devices. The resultant construct may be purified according to methods known in the art, such as high performance liquid chromatography (HPLC). Long, double-stranded polynucleotides, such as a DNA molecule of the present invention, must be synthesized in stages, due to the size limitations inherent in current oligonucleotide synthetic methods. Thus, for example, a 1.4 kb double-stranded molecule may be synthesized as several smaller segments of appropriate complementarity. Complementary segments thus produced may be annealed such that each segment possesses appropriate cohesive termini for attachment of an adjacent segment. Adjacent segments may be ligated by annealing cohesive termini in the presence of DNA ligase to construct an entire 1.4 kb double-stranded molecule. A synthetic DNA molecule so constructed may then be cloned and amplified in an appropriate vector.

[0085] Nucleic acid sequences of the present invention may also be isolated from appropriate biological sources using methods known in the art.

[0086] Also contemplated with the scope of the present invention are vectors or plasmids containing the nucleic acid sequence of SEQ ID NO: 1, and host cells or animals containing such vectors or plasmids. Methods for constructing vectors or plasmids containing the nucleic acid sequence of SEQ ID NO: 1, and host cells or animals containing the same are within the ability of persons skilled in the art of molecular biology.

SNPs, Polymorphisms, and Alleles

[0087] The genomes of all organisms undergo spontaneous mutation in the course of their continuing evolution, generating variant forms of progenitor genetic sequences (Gusella, Ann. Rev. Biochem. 55, 831-854 (1986)). The coexistence of multiple forms of a genetic sequence gives rise to genetic polymorphisms, including SNPs.

[0088] Approximately 90% of all polymorphisms in the human genome are SNPs. SNPs are single base positions in DNA at which different alleles, or alternative nucleotides, exist in a population. The SNP position (interchangeably referred to herein as SNP, SNP site, or SNP locus) is usually preceded by and followed by highly conserved sequences of the allele (e.g., sequences that vary in less than 1/100 or 1/1000 members of the populations). An individual may be homozygous or heterozygous for an allele at each SNP position. A SNP can, in some instances, be referred to as a "cSNP" to denote that the nucleotide sequence containing the SNP is an amino acid coding sequence.

[0089] A SNP may arise from a substitution of one nucleotide for another at the polymorphic site. Substitutions can be transitions or transversions. A transition is the replacement of one purine nucleotide by another purine nucleotide, or one pyrimidine by another pyrimidine. A transversion is the replacement of a purine by a pyrimidine, or vice versa. A SNP may also be a single base insertion or deletion variant referred to

as an "indel" (Weber et al., "Human diallelic insertion/deletion polymorphisms", *Am J Hum Genet* October 2002;71(4):854-62).

[0090] A synonymous codon change, or silent mutation/SNP (the terms "SNP" and "mutation" are used herein interchangeably), is one that does not result in a change of amino acid due to the degeneracy of the genetic code. A substitution that changes a codon coding for one amino acid to a codon coding for a different amino acid (i.e., a non-synonymous codon change) is referred to as a missense mutation. A nonsense mutation results in a type of non-synonymous codon change in which a stop codon is formed, thereby leading to premature termination of a polypeptide chain and a truncated protein. A read-through mutation is another type of non-synonymous codon change that causes the destruction of a stop codon, thereby resulting in an extended polypeptide product. While SNPs can be bi-, tri-, or tetra-allelic, the vast majority of the SNPs are bi-allelic, and are thus often referred to as "bi-allelic markers", or "di-allelic markers".

[0091] As used herein, references to SNPs and SNP genotypes include individual SNPs and/or haplotypes, which are groups of SNPs that are generally inherited together. Haplotypes can have stronger correlations with diseases or other phenotypic effects compared with individual SNPs, and therefore may provide increased diagnostic accuracy in some cases (Stephens et al. *Science* 293, 489-493, 20 Jul. 2001).

[0092] Causative SNPs are those SNPs that produce alterations in gene expression or in the expression, structure, and/or function of a gene product, and therefore are most predictive of a possible clinical phenotype. One such class includes SNPs falling within regions of genes encoding a polypeptide product, i.e. cSNPs. These SNPs may result in an alteration of the amino acid sequence of the polypeptide product (i.e., non-synonymous codon changes) and give rise to the expression of a defective or other variant protein. Furthermore, in the case of nonsense mutations, a SNP may lead to premature termination of a polypeptide product. Such variant products can result in a pathological condition, e.g., genetic disease. Examples of genes in which a SNP within a coding sequence causes a genetic disease include sickle cell anemia and cystic fibrosis.

[0093] Causative SNPs do not necessarily have to occur in coding regions; causative SNPs can occur in, for example, any genetic region that can ultimately affect the expression, structure, and/or activity of the protein encoded by a nucleic acid. Such genetic regions include, for example, those involved in transcription, such as SNPs in transcription factor binding domains, SNPs in promoter regions, in areas involved in transcript processing, such as SNPs at intron-exon boundaries that may cause defective splicing, or SNPs in mRNA processing signal sequences such as polyadenylation signal regions. Some SNPs that are not causative SNPs nevertheless are in close association with, and therefore segregate with, a disease-causing sequence. In this situation, the presence of a SNP correlates with the presence of, or predisposition to, or an increased risk in developing the disease. These SNPs, although not causative, are nonetheless also useful for diagnostics, disease predisposition screening, and other uses.

[0094] An association study of a SNP and a specific disorder involves determining the presence or frequency of the SNP allele in biological samples from individuals with the disorder of interest, such as AMD, and comparing the information to that of controls (i.e., individuals who do not have the disorder; controls may be also referred to as "healthy" or "normal" individuals) who are preferably of similar age and race. The appropriate selection of patients and controls is important to the success of SNP association studies. Therefore, a pool of individuals with well-characterized phenotypes is extremely desirable.

[0095] A SNP may be screened in diseased tissue samples or any biological sample obtained from a diseased individual, and compared to control samples, and selected for its increased (or decreased) occurrence in a specific pathological condition, such as pathologies related to AMD. Once a statistically significant association is established between one or more SNP(s) and a pathological condition (or other phenotype) of interest, then the region around the SNP can optionally be thoroughly screened to identify the causative genetic locus/sequence(s) (e.g., causative SNP/mutation, gene, regulatory region, etc.) that influences the pathological condition or phenotype. Association studies may be conducted within the general

population and are not limited to studies performed on related individuals in affected families (linkage studies).

[0096] As used herein, a "biological sample" refers to a sample of tissue or fluid isolated from an individual, including but not limited to, for example, blood, plasma, serum, tumor biopsy, urine, stool, sputum, spinal fluid, pleural fluid, nipple aspirates, lymph fluid, the external sections of the skin, respiratory, intestinal, and genitourinary tracts, tears, saliva, milk, cells (including but not limited to blood cells), tumors, organs, and also samples of *in vitro* cell culture constituent.

[0097] Clinical trials have shown that patient response to treatment with pharmaceuticals is often heterogeneous. There is a continuing need to improve pharmaceutical agent design and therapy. In that regard, SNPs can be used to identify patients most-suited to therapy with particular pharmaceutical agents (this is often termed "pharmacogenomics"). Similarly, SNPs can be used to exclude patients from certain treatment due to the patient's increased likelihood of developing toxic side effects or their likelihood of not responding to the treatment. Pharmacogenomics can also be used in pharmaceutical research to assist the drug development and selection process. (Linder et al. (1997), Clinical Chemistry, 43, 254; Marshall (1997), Nature Biotechnology, 15, 1249; International Patent Application WO 97/40462, Spectra Biomedical; and Schafer et al. (1998), Nature Biotechnology, 16, 3).

[0098] Particular SNP alleles, sometimes referred to as polymorphisms or polymorphic alleles, of the present invention can be associated with either an increased risk of having or developing AMD, or a decreased risk of having or developing AMD. SNP alleles that are associated with a decreased risk of having or developing AMD may be referred to as "protective" alleles, and SNP alleles that are associated with an increased risk of having or developing AMD may be referred to as "susceptibility" alleles or "risk factors". Thus, whereas certain SNPs (or their encoded products) can be assayed to determine whether an individual possesses a SNP allele that is indicative of an increased risk of having or developing AMD (i.e., a susceptibility allele), other SNPs (or their encoded products) can be assayed to determine whether an individual possesses a SNP allele that is indicative of a decreased risk of having or developing AMD (i.e., a protective allele). Similarly,

particular SNP alleles of the present invention can be associated with either an increased or decreased likelihood of responding to a particular treatment or therapeutic compound, or an increased or decreased likelihood of experiencing toxic effects from a particular treatment or therapeutic compound. The term "altered" may be used herein to encompass either of these two possibilities (e.g., an increased or a decreased risk/likelihood).

[0099] Those skilled in the art will readily recognize that nucleic acid molecules may be double-stranded molecules and that reference to a particular site on one strand refers, as well, to the corresponding site on a complementary strand. In defining a SNP position, SNP allele, or nucleotide sequence, reference to an adenine, a thymine (uridine), a cytosine, or a guanine at a particular site on one strand of a nucleic acid molecule also defines the thymine (uridine), adenine, guanine, or cytosine- (respectively) at the corresponding site on a complementary strand of the nucleic acid molecule. Thus, reference may be made to either strand in order to refer to a particular SNP position, SNP allele, or nucleotide sequence. Probes and primers, may be designed to hybridize to either strand and SNP genotyping methods disclosed herein may generally target either strand. Throughout the specification, in identifying a SNP position, reference is generally made to the protein-encoding strand, only for the purpose of convenience.

Assessment of Predisposition to AMD

[00100] The present invention also provides a method of assessing the relative susceptibility of a mammal (e.g. a human) to AMD. The "relative" susceptibility of a mammal to AMD refers to the fact that, among a population of individuals in a population at large, some individuals are more likely to develop AMD than others. This differential potential is attributable, at least in part to the genetic makeup of the individuals in the population.

[00101] In accordance with the present invention, it has been discovered that the presence of a certain polymorphism of the CFH gene is correlated with greater susceptibility to AMD in humans. Thus, the method of the invention for assessing the

relative susceptibility of an individual to AMD comprises determining whether the individual comprises a polymorphism in the *CFH* gene. One particularly preferred polymorphism is a C-allele at position 1277 of the *CFH* gene.

[00102] In conjunction with the genotyping methods of the present invention, one can also determine the presence of other known risk factors in an individual. For example, risk factors for development of complications of AMD including cigarette smoking, lack of exercise, hypertension, obesity (2, 21), and increased serum CRP levels or decreased serum CFH levels (22-25). Further, drusen with terminal complement deposition indistinguishable from AMD were observed in eyes from patients with a kidney disease (membranoproliferative glomerulonephritis type II) that can be caused by mutations in *CFH* (26, 27).

Methods of Treatment

[00103] The present invention also provides methods for treatment of a patient who has been determined to carry a variance in the human *CFH* gene, e.g., a pre-disposing allele to AMD. In one embodiment, the patient has not yet expressed any symptoms of ocular disease. In another embodiment, the patient expresses symptoms. Symptoms are known to those of skill in the art and may include blurred vision with the center of vision becoming blurred and the region growing larger as the disease progresses, straight lines may appear wavy and central vision loss can occur rapidly. It is recognized that no symptoms may be noticed if only one eye is affected.

[00104] Treatment can include prophylaxis, including agents which slow or prevent the progression of ocular disease such as AMD. In a preferred embodiment, the treatment includes any means to inhibit angiogenesis, such as, for example, angiogenesis inhibitor and more preferably, VEGF inhibitors. Such therapies may include laser based therapies to destroy blood vessels, such as photodynamic laser therapy (Visudyne®) or pegaptanib sodium (Macugen®). More preferably, the therapy is an angiogenesis inhibitor, such as a VEGF inhibitor. One preferred VEGF inhibitor is ranibizumab (Lucentis™). Other angiogenesis inhibitors and/or VEGF inhibitors are known to those of skill in the art and are useful in the treatment methods

of the present invention. Individuals diagnosed by the methods of the present invention as being susceptible to AMD may also wish to take vitamins and minerals such as, about 500 milligrams (mg) of vitamin C, about 400 international units (IU) of vitamin E, about 5 mg of beta-carotene, and about 80 mg of zinc oxide. Laser photocoagulation may also be useful in the treatment of individuals possessing a pre-disposing allele to AMD, especially in individuals where other symptoms are present. Other treatments encompassed by the present invention are Transpupillary Thermotherapy (TTT), Implantable Miniature Telescope (IMT), RHEO procedure, and the administration of anecortave acetate (Retaane[®]), Squalamine Lactate (EVIZON[™]), and Combretastatin.

[00105] The compounds used in connection with the treatment methods of the present invention are administered and dosed in accordance with good medical practice, taking into account the clinical condition of the individual patient, the site and method of administration, scheduling of administration, patient age, sex, body weight and other factors known to medical practitioners. The pharmaceutically "effective amount" for purposes herein is thus determined by such considerations as are known in the art. The amount must be effective to achieve improvement including, but not limited to, improved survival rate or more rapid recovery, or improvement or elimination of symptoms and other indicators as are selected as appropriate measures by those skilled in the art.

[00106] The methods of the present invention allow for the early detection of individuals susceptible to ocular diseases and cardiovascular diseases such as AMD. Thus, treatment may be initiated early, e.g. before or at the beginning of the onset of symptoms. The dosage required at these early stages will be lower than those needed at later stages of disease where the symptoms are severe. Such dosages are known to those of skill in the art and can be determined by the physician in response to the particular patient.

Kits

[00107] The present invention also provides a kit for performing the instant method disclosed herein. The kit comprises a plurality of reagents useful for performing the disclosed methods, and optionally further comprises an instructional material which describes how the method is performed.

[00108] By way of example, an exemplary kit for performing the allelic discrimination method of the invention comprises: a) a first oligonucleotide probe which anneals specifically with a target portion of the mammal's genome, wherein the target portion includes the nucleotide residue located at a polymorphic position of SEQ ID NO: 1, such as position 1277, the probe comprising a fluorescent label and a fluorescence quencher attached to separate nucleotide residues thereof, and b) a primer for amplifying a reference portion of corresponding wildtype allele of the CFH gene, the reference portion including the corresponding non-polymorphic (or wildtype) nucleotide residue, as defined by the sequence of SEQ ID NO: 1.

[00109] The kit may further comprise a DNA polymerase having 5'→3' exonuclease activity. The kit may also comprise a second oligonucleotide probe having a different annealing specificity than the first (e.g. wherein the first is completely complementary to the target portion of the C-allele at position 1277 of SEQ ID NO:1 and the second is completely complementary to the target portion of the T-allele at position 1277 of SEQ ID NO:1), a second primer (e.g. such that this and the other primer can be used to amplify at least the target portion by a PCR), or both. The kit may comprise an instructional material which can, for example, describe performance of the allelic discrimination method, the association between the presence of the C-allele and carcinogenic susceptibility, or both.

[00110] In an alternative embodiment of the present invention, the kit comprises at least one, and preferably two molecular beacon probes, as described herein. When the kit comprises two molecular beacon probes, one is preferably specific for (i.e. completely complementary to a region including the polymorphic nucleotide residue of SEQ ID NO: 1, e.g. nucleotide 1277) the polymorphic allele of the CFH gene, and the other is specific for the non-polymorphic allele. This kit may further comprise an

instructional material, including a publication, a recording, a diagram, or any other medium of expression which can be used to communicate the usefulness of the composition of the invention for performing a method of the invention or for associating the presence of a polymorphic allele of the CFH gene in an individual with susceptibility to AMD. The instructional material of the kit of the invention can, for example, be affixed to a container which contains a kit of the invention or be shipped together with a container which contains the kit. Alternatively, the instructional material can be shipped separately from the container with the intention that the instructional material and the kit be used cooperatively by the recipient.

[00111] Also provided by the present invention are kits for predicting the susceptibility of an individual to AMD according to the one or more of the methods of the invention. The kit comprises a plurality of reagents useful for performing one of the methods as described above, and optionally further comprises an instructional material which describes how the method is performed and the association between the presence of a polymorphic allele of CFH and AMD susceptibility.

[00112] Although the foregoing disclosure is principally directed to kits and methods which are applicable to human AMD, it will be understood by the skilled artisan that such methods and kits are generally applicable to mammals of all sorts. Modification, where necessary, of the kits and methods of the invention to conform to non-human AMD is well understood, and the ordinarily skilled veterinary worker can design and perform such modification with merely ordinary, if any, experimentation. Representative mammals include, for example, primates, cattle, pigs, horses, sheep, cats, and dogs.

Solid Supports

[00113] Solid supports containing oligonucleotide probes for identifying the alleles, including polymorphic alleles, of the present invention can be filters, polyvinyl chloride dishes, silicon or glass based chips, etc. Such wafers and hybridization methods are widely available, for example, those disclosed by Beattie (WO 95/11755). Any solid surface to which oligonucleotides can be bound, either

directly or indirectly, either covalently or noncovalently, can be used. A preferred solid support is a high density array or DNA chip. These contain a particular oligonucleotide probe in a predetermined location on the array. Each predetermined location may contain more than one molecule of the probe, but each molecule within the predetermined location has an identical sequence. Such predetermined locations are termed features. There may be, for example, about 2, 10, 100, 1000 to 10,000; 100,000, 400,000 or 1,000,000 of such features on a single solid support. The solid support, or the area within which the probes are attached may be on the order of a square centimeter.

[00114] Oligonucleotide probe arrays can be made and used according to any techniques known in the art (see for example, Lockhart et al. (1996), *Nat. Biotechnol.* 14: 1675-1689; McGall et al. (1996), *Proc. Nat. Acad. Sci. USA* 93: 13555-13460). Such probe arrays may contain at least two or more oligonucleotides that are complementary to or hybridize to two or more of the SNPs described herein. Such arrays may also contain oligonucleotides that are complementary or hybridize to at least about 2, 3, 4, 5, 6, 7, 8, 9, 10, 20, 30, 50 or more SNPs described herein.

[00115] Methods of forming high density arrays of oligonucleotides with a minimal number of synthetic steps are known. The oligonucleotide analogue array can be synthesized on a solid substrate by a variety of methods, including, but not limited to, light-directed chemical coupling, and mechanically directed coupling (see Pirrung et al. (1992), U.S. Pat. No. 5,143,854; Fodor et al. (1998), U.S. Pat. No. 5,800,992; Chee et al. (1998), U.S. Pat. No. 5,837,832).

[00116] In brief, the light-directed combinatorial synthesis of oligonucleotide arrays on a glass surface proceeds using automated phosphoramidite chemistry and chip masking techniques. In one specific implementation, a glass surface is derivatized with a silane reagent containing a functional group, e.g., a hydroxyl or amine group blocked by a photolabile protecting group. Photolysis through a photolithographic mask is used selectively to expose functional groups which are then ready to react with incoming 5' photoprotected nucleoside phosphoramidites. The phosphoramidites react only with those sites which are illuminated (and thus exposed by removal of the photolabile blocking group). Thus, the phosphoramidites only add

to those areas selectively exposed from the preceding step. These steps are repeated until the desired array of sequences have been synthesized on the solid surface. Combinatorial synthesis of different oligonucleotide analogues at different locations on the array is determined by the pattern of illumination during synthesis and the order of addition of coupling reagents.

[00117] In addition to the foregoing, additional methods which can be used to generate an array of oligonucleotides on a single substrate are described in Fodor et al., (1993). WO 93/09668. High density nucleic acid arrays can also be fabricated by depositing premade or natural nucleic acids in predetermined positions. Synthesized or natural nucleic acids are deposited on specific locations of a substrate by light directed targeting and oligonucleotide directed targeting. Another embodiment uses a dispenser that moves from region-to-region to deposit nucleic acids in specific spots.

Databases

[00118] The present invention includes databases containing information concerning polymorphic alleles associated with AMD, for instance, information concerning polymorphic allele frequency and strength of the association of the allele with AMD and the like. Databases may also contain information associated with a given polymorphism such as descriptive information about the probability of association of the polymorphism with AMD. Other information that may be included in the databases of the present invention include, but is not limited to, SNP sequence information, descriptive information concerning the clinical status of a tissue sample analyzed for SNP haplotype, or the subject from which the sample was derived. The database may be designed to include different parts, for instance a SNP frequency database and a SNP sequence database. Methods for the configuration and construction of databases are widely available, for instance, see Akerblom et al., (1999) U.S. Pat. No. 5,953,727, which is herein incorporated by reference in its entirety.

[00119] The databases of the invention may be linked to an outside or external database. In a preferred embodiment, the external database may be the HGBASE

database maintained by the Karolinska Institute, The SNP Consortium (TSC) and/or the databases maintained by the National Center for Biotechnology Information (NCBI) such as GenBank.

[00120] Any appropriate computer platform may be used to perform the necessary comparisons between polymorphic allele frequency and associated disorder and any other information in the database or provided as an input. For example, a large number of computer workstations are available from a variety of manufacturers, such as those available from Silicon Graphics. Client-server environments, database servers and networks are also widely available and appropriate platforms for the databases of the invention.

[00121] The databases of the invention may also be used to present information identifying the polymorphic alleles in a subject and such a presentation may be used to predict the likelihood that the subject will develop AMD. Further, the databases of the present invention may comprise information relating to the expression level of one or more of the genes associated with the polymorphic alleles of the invention.

[00122] The polymorphisms identified by the present invention may be used to analyze the expression pattern of an associated gene and the expression pattern correlated to the probability of developing an AMD. The expression pattern in various tissues can be determined and used to identify tissue specific expression patterns, temporal expression patterns and expression patterns induced by various external stimuli such as chemicals or electromagnetic radiation.

[00123] The following examples are provided to illustrate certain embodiments of the invention. They are not intended to limit in any way the remainder of the disclosure.

EXAMPLES

Complement Factor H Polymorphism and Age-Related Macular Degeneration

[00124] Age-related macular degeneration (AMD) is a leading cause of blindness in older individuals (1). It is a late-onset, complex trait with hereditary, lifestyle, and medical risk factors (2). The condition typically presents in the fifth decade of life

with small yellow deposits external to the outer retina and retinal pigment epithelium (RPE) called drusen. Large numbers of drusen and clinical features of damage to the RPE markedly increase the risk of complications (atrophy of the RPE and abnormal neovascularization of the outer retina), leading to severe vision loss (1).

[00125] Although the primary pathogenic mechanisms of AMD were previously unknown, there is strong evidence that genetics plays a role (3-9). The first locus for AMD (*ARMD1*) was reported in a single extended family linked to chromosome 1q25.3-31.3 (5). Because there was strong evidence for linkage to this region of chromosome 1 from subsequently reported small family studies, we focused our efforts on the *ARMD1* locus (3, 4, 6, 8, 9).

Source of research subjects:

[00126] Cases were patients of one of the authors (A.O.E.) and were prospectively and consecutively ascertained under a protocol approved by the University of Texas Southwestern (UTSW) Medical Center Institutional Review Board. All patients with any stage of age-related macular degeneration (AMD) were invited to participate by providing health information, diagnostic documentation, and a blood sample. Only patients unable to provide a blood sample and those who refused to participate were excluded. Patients were seen for management and follow up regardless of severity of disease, manifestations of disease, or presence of complications. The data are derived from a subpopulation of case and control individuals of European descent who met certain diagnostic criteria set forth below.

[00127] Controls were primarily patients of A.O.E. and other UTSW physicians and were over the age of 50 without a family history of AMD. Spouses of AMD patients were also prospectively recruited and spouses of UTSW patients were enrolled when possible. The spouses often obtained their medical care at UTSW Medical Center. Thus, the controls were selected from the same pool of patients receiving medical care at UTSW Medical Center as the cases. We attempted to obtain controls with a similar age distribution as the cases by ascertaining spouses and recruiting subjects age 60 or older. Potential controls were recruited for a screening

examination. If the potential control subject met certain diagnostic criteria set forth below, fundus photography and full enrollment were performed.

Examination of research subjects:

[00128] Cases had a comprehensive ocular examination as a part of their regular medical care. Color fundus photographs were performed as indicated for their regular medical care or specifically for the study.

[00129] Potential control subjects were screened using a brief questionnaire to exclude individuals with a family history of AMD or ocular diseases that might simulate AMD or preclude its diagnosis such as prior laser photocoagulation, cryopexy, media opacity, and inflammatory diseases. Screened subjects were scheduled for a limited research eye examination that included visual acuity with correction, slit lamp evaluation of the anterior segment and vitreous, and biomicroscopy of the optic nerve head and macula. Potential control subjects were excluded for media opacity (e.g., cataract) preventing excellent visualization of the macula, diseases with phenotypic overlap with AMD such as drusen or pigmentary disturbance of the RPE insufficient to diagnose AMD, pattern dystrophies, toxoplasmosis, histoplasmosis, high myopia, central serous chorioretinopathy, or any disease or treatment that would diminish the ability to recognize drusen such as laser photocoagulation, macula involving retinal detachment, posterior uveitis, and trauma. Inclusion criteria were less than five small (< 63 micron) hard drusen, at least 20/40 view of the fundus, and absence of exclusion criteria. Fundus photographs and a blood sample were taken on subjects meeting these criteria by eye examination. The examination findings for both cases and controls were systematically documented and a tentative diagnosis assigned in the clinic after the examination.

Diagnosis of research subjects:

[00130] The fundus photographs and examination notes were reviewed prior to the selection of case and control subjects for genotyping (Table 2). Discrepancies between the examination and fundus photographs were resolved by reevaluating the

subject or selecting the more conservative diagnostic evaluation. Thus, features noted on examination but not visible on fundus photography were used to exclude control subjects but not to enroll AMD subjects. The medical records, examination notes, and fundus photographs were reviewed as collected and at least one additional time prior to selecting the subject for genotyping.

[00131] The AMD cases had one or more drusen ≥ 63 microns in diameter documented at some point during their disease course (S1). The minimum disease severity required for inclusion was high risk AMD defined as sufficient drusen in the macula to fill a circle 700 microns in diameter or drusen with more advanced features such as retinal pigment epithelial hyperplasia. The presence of these features is predictive of significant risk for developing complications of AMD such as exudation and has been used previously in AMD genetics studies (S2-4). Cases were diagnosed as (i) high risk, early AMD, (ii) AMD with pure geographic atrophy, or (iii) AMD with exudation using standard criteria (S1).

[00132] Hard drusen are common in subjects over the age of 50 (S5). The Beaver Dam Eye Study longitudinal data and our own cross-sectional observations with families segregating AMD support extensive hard drusen as a precursor to larger drusen and pigmentary abnormalities diagnostic of AMD (S6). Eight or more hard drusen doubled the 10-year incidence of AMD (S6). As noted above, we chose a conservative criterion of less than 5 hard drusen and the absence of more advanced features for enrollment of control subjects.

Disease features of AMD subjects:

[00133] A total of 400 AMD subjects were included in this study. The distribution of subjects was: 47% high risk, early AMD; 16% drusen-associated AMD complicated by pure geographic atrophy; and 37% drusen-associated AMD complicated by exudation. Patients with exudation and geographic atrophy are referred to as late AMD. Thus, 53% of subjects had late AMD.

Selection of samples for genotyping:

[00134] A subset of AMD subjects was selected for initial genotyping and designated the discovery sample. This sample preferentially included 83 probands with a family history consistent with dominant transmission of AMD toward the goal of potentially increasing our power to detect a genetic effect. The discovery sample preferentially included 119 subjects with high-risk, early AMD because these subjects were closer in age to the control population. The remaining subjects in the discovery sample were exudative with a family history of AMD that was not consistent with dominant transmission. A total of 224 AMD subjects and 134 control subjects made up the discovery sample.

[00135] The remainder of the subjects already available at the time of the selection of the discovery sample (161 subjects) and subsequently ascertained subjects (244 subjects) were prospectively utilized as a replication sample.

Genotyping*SNP selection, assay design, and validation:*

[00136] All SNPs intended for genotyping were selected from the public domain, as reported by www.ensembl.org and <http://www.ncbi.nlm.nih.gov/SNP/snpLocus.html>. SNPs with known allele frequencies were selected on the basis of conferring amino acid substitutions in encoded proteins (non-synonymous coding SNPs) or for approximately equal spacing throughout genes (gene-based SNPs).

[00137] Genotyping was performed using either TaqMan[®] SNP genotyping assays (Applied Biosystems, Foster City, CA) or the MassARRAY[®] platform (SEQUENOM, San Diego, CA). Custom TaqMan SNP genotyping probes (S7) for each allele were designed using Primer Express[®] v2.0 software (Applied Biosystems) using recommended guidelines (S8). Successful discrimination of each allele was verified using 31 Caucasian population control individuals. Genomic DNA (20 ng) was

amplified according to assay recommendations and genotyping analysis was performed using an ABI Prism[®] 7900HT. Assays that failed to discriminate alleles from any control population sample were either redesigned and retested or not used for further genotyping analysis.

[00138] Alternatively, sequences containing SNPs were used in multiplex assay designs using proprietary software SpectroDESIGNER[®]. Designed assays were validated using 25 ng of a genomic DNA pool containing an equimolar mix of DNA from 92 unrelated individuals of European ancestry derived from the Centre d'Etude du Polymorphisme Humaine (Paris) panel (S9, 10). Assays were analyzed by MALDI-TOF mass spectrometry on the MassARRAY platform, and allele frequencies within the DNA pool were estimated as described (S9). Working assays for SNPs with minor allele frequencies estimated at approximately 0.1 and higher were employed for all SNP assays presented in this manuscript.

Genotyping of discovery and replication samples

[00139] TaqMan SNP assays for genotyping were performed in the same manner as for validating the assays. For the MassARRAY platform, genotyping was performed as described (S9, 11-14). Briefly, sequences containing target SNPs were amplified from 2.5 ng genomic DNA in reactions including from one to six multiplexed assays. Unincorporated dNTPs following PCR were eliminated using shrimp alkaline phosphatase. Amplification products were then used in MassEXTEND[®] reactions to generate allele-specific products. EXTEND oligonucleotides annealing immediately adjacent to amplified target SNPs were extended using a DNA polymerase in the presence of a dNTP/ddNTP mix to generate primer extension products differing in length and mass as specified by the SNP alleles. Following brief treatment with resin to desalt the reactions, aliquots of EXTEND reaction products were deposited onto 384-array microchips and analyzed by MALDI-TOF mass spectrometry. Individual mass spectra were processed in real-time by proprietary SpectroTYPER software using baseline correction and peak

identification algorithms to determine alleles based on input assay design parameters. Quality control of genotype calls was then performed post-real time using proprietary GenoQC software, which plots individual calls on an X-Y grid and evaluates the statistical likelihood of each call belonging to the genotype class to which it was assigned in real-time.

Statistical analyses

Subject demographics

[00140] Differences in mean age and presence or absence of family history in the discovery and replication samples were evaluated using the t-test.

Hardy-Weinberg equilibrium

[00141] Hardy-Weinberg equilibrium (HWE) implies that in a sample of subjects selected from a larger population, the SNP genotype frequencies can be predicted from the allele frequencies. Specifically, if 'p' is the population frequency of allele 'A' and 'q' is the population frequency of allele 'B', the frequency of the genotypes, AA, AB, and BB should fit the distribution of $p^2 + 2pq + q^2 = 1$ to be in HWE (S15). All SNPs reported in this study met HWE conditions.

Allele and genotype analyses

[00142] Allele and genotype frequency distributions were compared between cases and controls using a χ^2 goodness-of-fit test. Because the cases were significantly older than controls at the time of entry into the study, these analyses were repeated using logistic regression models adjusting for age. However, this adjustment did not change the significance level or patterns of association. Analyses were carried out using the SAS System, Release 8.02, SAS Institute Inc, Cary, NC, 2002.

Haplotype analysis

[00143] We examined haplotype block structures and generated haplotypes in these blocks using the Haploview software (S16). This approach assumes that all subjects are unrelated and that all haplotypes are ambiguous due to unknown linkage phase of the SNPs. The resultant block structure was determined using the algorithm of Gabriel *et al.* (S17). Within each block, at least 95% of informative pair-wise SNP comparisons show strong LD (i.e., the LD statistic, D' (S15), is 0.8 or greater). Comparisons of marker haplotypes with AMD were carried out using the haplo.score function of the Haplo.Stats program (ver 1.1.1) by D. Schaid, J. Sinnwell, C. Rowland, D. Tines (Mayo Clinic) web: <http://www.mayo.edu/hsr/people/schaid.html>; and Haploview 3.0 by J. Barrett (Whitehead Institute) web: <http://www.broad.mit.edu/personal/jcbarret/haploview/>. The resultant statistic for the global test of association fits an asymptotic χ^2 distribution. Comparison were made to the HapMap data (S18).

Attributable risk

[00144] The measurement of attributable fraction (AF) for the CC and CT genotypes at Try402His was calculated using formulas which consider the frequency of CC and CT in the cases:

Error! Objects cannot be created from editing field codes. or controls: Error!
Objects cannot be created from editing field codes. where f is the fraction of cases or controls with CC and CT, and R is the measure of relative risk. For more information on attributable fraction for genetic traits, see Khoury MJ, Beaty TH, Cohen BH. Fundamentals of Genetic Epidemiology. New York, Oxford University Press, 1993, pp. 77-79.

Evaluation of the Fibulin 6 gene

[00145] A rare Q5346R variation in a conserved amino acid of the Fibulin 6 gene (*FIBL6*) was proposed as the mutation causing AMD in the original family (AMD30) defining the ARMD1 locus (*SI9*). Even though this protein is a candidate gene for AMD based on homology to an early-onset hereditary macular disease characterized by dominant radial drusen, the variation was not associated with AMD in multiple studies (*S4, 19-24*). We observed a single case (224 genotyped subjects) and a single control (134 genotyped subjects) with the Q5346R variation giving a combined frequency of 0.0056.

[00146] While the Q5346R variation cannot account for the observed linkage to 1q25.3-31.3 in small family studies, the possibility of other variation in *FIBL6* contributing to the linkage signal has not been excluded. To address this possibility, we performed allele association studies by genotyping 23 SNPs across *FIBL6* spaced at an average density of 20 kb in the discovery sample (Table 4). The individual polymorphisms and haplotypes derived from them were not associated with AMD. Thus, genetic variation across the 456 kb *FIBL6* locus is

[00147] unlikely to contribute to the linkage signal on chromosome 1q25.3-31.3 and to AMD susceptibility in our case-control sample.

Results

[00148] We performed an allele association study on a new case-control population highly discordant for clinical phenotypes. Cases were enrolled based on ocular features (extensive drusen or pigmentary abnormalities of the macula) placing subjects at high risk for development of the complications of AMD or the presence of those complications in one or both eyes (*10*). Control subjects were from the same patient population and could have no more than four small hard drusen in the central retina (macula) and no known family history of AMD. A subset of 224 cases and 134 controls meeting these criteria were selected as a discovery sample for initial genotyping (Table 2). The discovery sample was enriched for AMD cases showing familial clustering of AMD and high-risk, early AMD. A second, replication sample

of 176 cases and 68 controls was ascertained at the same clinic following the same protocol (Table 2).

[00149] Evaluation of the reported Q5346R variation in the Fibulin 6 gene (*FIBL6*) and 23 SNPs across this gene (supporting online text) gave no evidence for allele or haplotype association in the discovery sample (11). To determine if common coding sequence variation within the *ARMD1* locus was associated with AMD, we searched publicly available databases for non-synonymous coding SNPs (nscSNPs). We identified 24 nscSNPs with known minor allele frequency of at least 10% across the 14 Mb *ARMD1* locus. Genotyping of the discovery sample gave significant allele and genotype association between AMD and nscSNPs only within the regulation of complement activation (RCA) locus in chromosome 1q31.3 (Table 3). Additional evenly spaced, gene-based SNPs were evaluated across all 31 genes in clusters 1, 2, 4, and 6 at 8 kb to 25 kb density (Fig. S1) and no associations with AMD were detected outside of the RCA locus (Table 4). These data suggest the RCA locus contains one or more genetic variants increasing the risk of developing AMD.

[00150] The RCA locus spans 388 kb of genomic DNA that contains the gene encoding complement factor H (*CFH*), five genes derived from *CFH* through ancestral duplications, and the gene encoding factor 13B (Fig. 1). A total of 86 SNPs located across the RCA locus and flanking regions were genotyped. Twenty-nine gave evidence for allele association with the majority and most significant of these, including the nscSNP rs1061170, concentrated in the *CFH* gene (Table 4, GenBank accession NM_000186).

[00151] The genotype frequency data for rs1061170 revealed that the association with AMD was largely due to an excess of CC homozygotes in cases compared to controls (Table 1). A similar pattern of association was evident with seven adjacent SNPs in *CFH* (Fig. 1 and Table 4). The strength of the evidence for association diminished markedly with SNPs located immediately proximal to *CFH* and distal to its derivatives *CFHL1-CFHL5*, suggesting that the effect was due to one or more polymorphisms in the complement factor genes only (Fig. 1 and Table 4).

[00152] Haplotype analyses of 34 SNPs spanning 418 kb revealed extensive linkage disequilibrium across the full length of the RCA locus (Fig. 2). The highest

level of linkage disequilibrium discernable among 4 haplotype blocks was across the RCA locus. Thirteen contiguous SNPs in *CFH* (i.e., all but the first two *CFH* SNPs in Fig. 2) form a 64 kb haplotype block. A second 9 kb haplotype block contained SNPs in the proximal portion of *CFHLA*, a third 50 kb block contained SNPs in the distal portion of *CFHLA* and SNPs in *CFHL2*, and a fourth 146 kb block contained SNPs in *F13B*, *ASPM* and *FRBZ1* (Fig. 2). The SNPs most significantly associated with AMD were in *CFH* or within 221 kb downstream of *CFH* (Fig. 1 and Table 4).

[00153] The association between AMD and haplotypes comprising 2-5 contiguous SNPs was evaluated using the Haplo.stat software by a sliding window approach (12, 13). Additional comparisons were made using all possible haplotypes formed by pair wise combinations including at least one nscSNP within the RCA locus. The analysis did not reveal any SNP combination showing greater association with AMD than the individual SNPs. All of the AMD high-risk haplotypes including a *CFH* SNP from haplotype block 1 and a non-*CFH* SNP from other regions of the RCA locus (Fig. 1) contained the AMD risk allele from the *CFH* SNP but not necessarily the AMD risk allele from the non-*CFH* SNP. These analyses provide further evidence that the multiple signals in the RCA locus are related to a single haplotype and therefore likely caused by a single genetic effect.

[00154] To verify these findings, we genotyped 14 SNPs in the RCA locus in the replication sample. Association with AMD was observed with the 7 markers that were significant in the discovery sample, including rs1061170, but not with the 7 markers yielding negative results in the discovery sample (Table 5). Notably, the genotype frequencies for rs1061170 among cases enriched for a positive family history of AMD were nearly identical to the frequencies among cases without this characteristic (Table 1), suggesting that this *CFH* protein polymorphism is a risk factor for AMD more generally. Taking into account data from the entire sample, a conservative estimation of the relative risk for AMD conferred by having at least one C allele (i.e., having either the CC or CT genotypes) was 2.7 (95% CI = 1.9–3.9).

[00155] Complement activation has been implicated in the pathogenesis of a number of complex traits including AMD and can arise through the classical, lectin, or alternative pathways (14). All three pathways lead to the generation of a C3

convertase enzyme and subsequent activation of the immune response, the terminal pathway pore-like membrane attack complex (C5b-9), and cell lysis. The alternative complement pathway is spontaneously activated and CFH is an essential inhibitor preventing uncontrolled complement activation (15). Components of the terminal complement pathway and other markers of inflammation are deposited in drusen and the choroid of eyes with AMD (16, 17). Abnormal regulation of the alternative pathway of complement activation by CFH is consistent with these observations.

[00156] The tyrosine to histidine polymorphism (rs1061170) at amino acid 402 of CFH appears to be a primary pathogenic variation increasing the risk of developing AMD. CFH is composed of 20 repetitive units of 60 amino acids called short consensus repeats (SCRs). The Tyr402His polymorphism is located within SCR7, which contains the overlapping binding sites for heparin, C-reactive protein (CRP), and M-protein (18). Serum levels of CRP were elevated in AMD subjects compared to controls in one large prospective clinical trial (19). CRP activates the classic complement pathway, but reduces deposition of C5b-9 through the direct binding of CFH (20). Risk factors for development of complications of AMD including cigarette smoking, lack of exercise, hypertension, and obesity (2, 21) increased serum CRP levels or decreased serum CFH levels (22-25). Further, drusen with terminal complement deposition indistinguishable from AMD were observed in eyes from patients with a kidney disease (membranoproliferative glomerulonephritis type II) that can be caused by mutations in *CFH* (26, 27). In principle, altered binding of CFH to CRP or heparin on outer retinal surfaces caused by the Tyr402His substitution could affect the level of inflammation in the outer retina, thereby contributing to AMD. Although our results are consistent with the Tyr402His variant causing AMD, they do not rule out the existence of other coding or splice site variants within *CFH* that modulate risk of AMD.

[00157] More than 7 million individuals in the United States have retinal features placing them at high risk for developing vision loss from complications of AMD (28). The attributable fraction for the C allele derived from the total sample of subjects in this study is 50%, indicating that persons either homozygous or heterozygous for histidine at amino acid 402 of CFH account for one-half of AMD cases. Given the

rapid aging of the population, an estimated 3 million individuals will have atrophic and exudative complications of AMD by 2020 (28).

Table I. Association between the Try402His polymorphism (rs1061170) in *CFH* and AMD. The C allele codes for histidine. The genotype association compares CC to CT and TT.

Sample	Allele distribution			Allele Association (<i>P</i> -value)	Genotype distribution			Genotype Association (<i>P</i> -value)
	Cases	Controls			Cases	Controls		
Discovery	C	0.553	0.340	3.68×10^{-8}	CC	0.320	0.115	7.67×10^{-7}
	T	0.447	0.660		TC	0.467	0.450	
					TT	0.213	0.435	
Replication	C	0.544	0.390	0.0039	CC	0.306	0.186	0.0135
	T	0.456	0.610		TC	0.477	0.407	
					TT	0.218	0.407	
Total	C	0.549	0.355	4.95×10^{-10}	CC	0.314	0.137	1.4×10^{-8}
	T	0.451	0.645		TC	0.471	0.437	
					TT	0.215	0.426	

Table 2: Demographics of the Discovery and Replication Case-Control Samples

Sample	Number of subjects	Percent Male	Mean Age at Entry (SD)	Percent with Family History of AMD
Discovery				
AMD Cases	224	58	72.7 (10.1)	46.7
Controls	134	42	67.6 (7.6)	0
Replication*				
AMD Cases	176	65	78.2 (7.9)	18.8
Controls	68	35	68.1 (9.0)	0

* As expected from the selection criteria, the cases in the replication sample had a lower percentage of family history of AMD ($P = 1.0 \times 10^{-12}$) and an older age at entry into the study ($P = 2.7 \times 10^{-6}$) compared with cases in the discovery sample

Table 3. Allele and genotype association between AMD and polymorphic non-synonymous coding SNPs (nscSNPs) in the 14 Mb ARMD1 locus.

Gene	Cluster*	nscSNP	Map Position	P-value for Association with AMD**	
				Allele	Genotype
<i>LAMC2</i>	1	rs11586699	179916347	0.26	0.42
<i>LAMC2</i>	1	rs2296306	179922981	0.62	0.62
<i>LAMC2</i>	1	rs2296303	179933627	0.22	0.45
<i>C1orf16</i>	1	rs2298083	180247085	0.43	0.59
<i>NCF2</i>	1	rs2274064	180274044	0.32	0.16
<i>MGC26594</i>	1	rs1174657	180348583	0.51	0.78
<i>MGC26594</i>	1	rs1174658	180348762	0.76	0.91
<i>C1orf19</i>	1	rs1046934	180755186	0.40	0.35
<i>C1orf22</i>	2	rs9425343	181395194	0.99	0.99
<i>C1orf26</i>	2	rs10489579	181875378	0.34	0.54
<i>C1orf26</i>	2	rs6698109	181903526	0.99	0.79
<i>C1orf26</i>	2	rs12041704	181972131	0.25	0.46
<i>FIBL6</i>	3	rs7539719	182690394	0.38	0.12
<i>PRG4</i>	3	rs2273779	183005651	0.88	0.98
<i>TPR</i>	3	rs3753565	183048145	0.35	0.64
<i>C1orf27</i>	3	rs12084264	183094776	0.99	1.0
<i>GLRX2</i>	5	rs10921310	189806308	0.09	0.11
<i>CFH</i>	6	rs800292	193373890	0.0009	0.0022
<i>CFH</i>	6	rs1061170	193390894	3.68×10^{-8}	7.67×10^{-7}
<i>CFH</i>	6	rs1065489	193441431	0.98	0.69
<i>CFHL4</i>	6	rs379370	193615850	0.0004	0.0012
<i>F13B</i>	6	rs6003	193762678	0.0029	0.0038
<i>ASPM</i>	6	rs3762271	193802099	0.56	0.21
<i>ASPM</i>	6	rs12138336	193802178	0.80	0.42

* Please refer to Figure 1, **All SNPs presented in this manuscript were in Hardy-Weinberg equilibrium. Additional genotype data is presented in Table 4.

Table 4. Genotyping in the discovery sample: Allele and genotype association between AMD and all 236 polymorphic SNPs across gene clusters 1-6 of the ARMD1 locus.*

Cluster	SNP Name	Location	Allele Counts			χ^2_{1df}	Genotype Counts			χ^2_{2df}
			AMD	Control	p-value	Test	AMD	Control	p-value	Test
1	rs4593781	179716640	C	195	129	0.25	CC	40	29	0.50
			T	251	139		CT	115	71	
							TT	68	34	
1	rs4129857	179736204	A	237	135	0.34	AA	63	33	0.62
			G	189	125		AG	111	69	
							GG	39	28	
1	rs6664995	179749002	C	248	138	0.35	CC	66	34	0.63
			T	196	126		CT	116	70	
							TT	40	28	
1	rs7547953	179763298	G	250	140	0.29	GG	67	34	0.55
			T	194	128		GT	116	72	
							TT	39	28	
1	rs4397624	179784788	C	188	122	0.49	CC	38	26	0.76
			T	234	136		TC	112	70	
							TT	61	33	
1	rs7542640	179795395	A	255	139	0.23	AA	71	35	0.47
			G	187	123		GA	113	69	
							GG	37	27	
1	rs1537520	179815886	C	184	116	0.42	CC	37	24	0.68
			T	252	140		TC	110	68	
							TT	71	36	
1	rs1886499	179826681	C	192	125	0.32	CC	39	27	0.59
			T	256	143		TC	114	71	
							TT	71	36	
1	rs3768616	179835208	A	182	119	0.20	AA	36	26	0.41
			G	250	133		AG	110	67	
							GG	70	33	
1	rs729672	179840893	C	185	121	0.36	CC	39	28	0.65

Cluster	SNP Name	Location	Allele Counts			Test	Genotype Counts			Test
			AMD	Control	p-value		AMD	Control	p-value	
			T 235	133			CT 107	65		
							TT 64	34		
1	rs7473	179846291	A 250	140	0.35		AA 69	36	0.63	
			G 188	122			GA 112	68		
							GG 38	27		
1	rs7513264	179880946	C 221	136	0.80		CC 58	37	0.95	
			G 203	120			CG 105	62		
							GG 49	29		
1	rs544352	179889203	A 228	130	0.58		AA 60	31	0.76	
			G 206	128			AG 108	68		
							GG 49	30		
1	rs552361	179899515	C 283	168	0.80		CC 86	57	0.30	
			T 165	94			TC 111	54		
							TT 27	20		
1	rs635796	179909111	C 242	157	0.27		CC 68	48	0.54	
			T 200	109			TC 106	61		
							TT 47	24		
1	rs11586699	179916347	C 409	250	0.26		CC 190	118	0.42	
			T 33	14			CT 29	14		
							TT 2	0		
1	rs3814337	179919719	C 347	194	0.30		CC 137	75	0.40	
			T 85	58			TC 73	44		
							TT 6	7		
1	rs2296303	179933627	C 68	50	0.22		CC 4	4	0.45	
			G 382	218			CG 60	42		
							GG 161	88		
1	rs1925043	179939260	A 343	198	0.46		AA 137	79	0.45	
			G 81	54			AG 69	40		
							GG 6	7		
1	rs649954	179948105	C 357	207	0.60		CC 141	84	0.23	
			T 89	57			TC 75	39		
							TT 7	9		

Cluster	SNP Name	Location	Allele Counts			χ^2_{1df} Test		Genotype Counts			χ^2_{2df} Test	
			AMD	Control	p-value			AMD	Control	p-value		
1	rs2105160	179957786	C	87	56	0.62		CC	6	8	0.26	
			G	359	210			CG	75	40		
								GG	142	85		
1	rs2301877	179990782	C	274	160	0.35		CC	82	56	0.17	
			T	172	86			CT	110	48		
								TT	31	19		
1	rs7521935	180001747	C	322	191	0.88		CC	116	68	0.98	
			G	120	73			GC	90	55		
								GG	15	9		
1	rs951420	180011569	A	74	56	0.11		AA	4	6	0.20	
			G	372	206			GA	66	44		
								GG	153	81		
1	rs1411392	180021707	C	142	71	0.14		CC	21	5	0.13	
			T	300	193			CT	100	61		
								TT	100	66		
1	rs953274	180031538	C	205	125	0.99		CC	43	29	0.75	
			T	225	137			TC	119	67		
								TT	53	35		
1	rs1541170	180041475	C	298	191	0.17		CC	100	66	0.22	
			T	140	71			TC	98	59		
								TT	21	6		
1	rs649614	180051849	A	252	154	0.63		AA	67	45	0.68	
			G	194	110			AG	118	64		
								GG	38	23		
1	rs2811558	180062070	G	240	143	0.99		GG	59	39	0.56	
			T	206	123			TG	122	65		
								TT	42	29		
1	rs2225932	180084222	C	388	224	0.30		CC	169	95	0.57	
			T	58	42			TC	50	34		
								TT	4	4		
1	rs2788060	180094303	C	244	145	0.97		CC	62	41	0.52	
			T	198	117			TC	120	63		

Cluster	SNP Name	Location	Allele Counts		χ^2 1 df	Test	Genotype Counts		χ^2 2 df	
			AMD	Control	p-value		AMD	Control	p-value	
1	rs3120798	180105322	C	306	189	0.72	TT	39	27	0.88
			T	136	79		CT	100	61	
						TT	18	9		
1	rs4652800	180115300	C	194	113	0.71	CC	38	26	0.38
			T	238	147		TC	118	61	
						TT	60	43		
1	rs2811551	180129246	A	301	183	0.58	AA	102	62	0.70
			C	139	77		AC	97	59	
						CC	21	9		
1	rs2275675	180171140	A	284	167	0.81	AA	88	46	0.32
			G	162	99		AG	108	75	
						GG	27	12		
1	rs2702176	180181558	A	45	26	0.95	AA	2	2	0.83
			G	397	226		GA	41	22	
						GG	178	102		
1	rs2702200	180208888	C	193	110	0.74	CC	48	20	0.15
			T	243	146		TC	97	70	
						TT	73	38		
1	rs789169	180218516	A	396	242	0.90	AA	178	111	0.45
			G	44	26		AG	40	20	
						GG	2	3		
1	rs2877978	180228315	A	287	170	0.77	AA	99	54	0.21
			G	149	84		GA	89	62	
						GG	30	11		
1	rs2298083	180247085	A	53	39	0.23	AA	2	1	0.38
			G	387	217		GA	49	37	
						GG	169	90		
1	rs2702182	180248097	C	284	165	0.85	CC	90	47	0.36
			T	162	97		TC	104	71	
						TT	29	13		
1	rs699245	180252940	C	229	124	0.25	CC	62	24	0.08

Cluster	SNP Name	Location	Allele Counts			Test	Genotype Counts			Test
			AMD	Control	p-value		AMD	Control	p-value	
			T	213	138		CT	105	76	
							TT	54	31	
1	rs789181	180257995	A	397	236	0.91	AA	178	108	0.44
			G	45	26		GA	41	20	
							GG	2	3	
1	rs2296164	180266592	C	236	125	0.25	CC	61	25	0.23
			T	210	133		CT	114	75	
							TT	48	29	
1	rs2274064	180274044	A	234	128	0.32	AA	61	25	0.16
			G	216	138		GA	112	78	
							GG	52	30	
1	rs699242	180278130	C	83	41	0.29	CC	10	4	0.59
			T	359	221		CT	63	33	
							TT	148	94	
1	rs4987079	180291853	A	40	31	0.26	AA	0	1	0.29
			G	404	235		AG	40	29	
							GG	182	103	
1	rs2333685	180297646	C	164	96	0.65	CC	32	19	0.86
			T	254	160		CT	100	58	
							TT	77	51	
1	rs11755	180327793	C	211	125	0.80	CC	52	32	0.85
			T	219	135		CT	107	61	
							TT	56	37	
1	rs2767305	180336562	A	227	132	0.70	AA	60	40	0.46
			G	205	112		AG	107	52	
							GG	49	30	
1	rs1174656	180348344	A	147	85	0.71	AA	31	18	0.92
			G	281	173		GA	85	49	
							GG	98	62	
1	rs1174657	180348583	C	169	94	0.51	CC	36	20	0.78
			T	275	170		CT	97	54	
							TT	89	58	

Cluster	SNP Name	Location	Allele Counts			χ^2_{1df}	Genotype Counts			χ^2_{2df}
			AMD	Control	p-value	Test	AMD	Control	p-value	Test
1	rs1174658	180348762	A	268	161	0.76	AA	80	50	0.91
			G	180	103		AG	108	61	
							GG	36	21	
1	rs1174679	180378011	C	163	93	0.67	CC	29	19	0.57
			T	283	173		TC	105	55	
							TT	89	59	
1	rs4609393	180420923	C	199	127	0.50	CC	44	32	0.66
			T	225	129		TC	111	63	
							TT	57	33	
1	rs1073848	180430171	A	232	133	0.61	AA	59	35	0.69
			G	129	129		GA	114	63	
							GG	47	33	
1	rs6658466	180441005	C	237	136	0.63	CC	60	35	0.79
			T	211	130		TC	117	66	
							TT	47	32	
1	rs6684415	180450187	A	271	171	0.86	AA	86	58	0.64
			T	155	95		TA	99	55	
							TT	28	20	
1	rs6679538	180468213	C	280	171	0.74	CC	87	58	0.50
			T	164	95		TC	106	55	
							TT	29	20	
1	rs6676389	180476550	A	253	156	0.51	AA	72	48	0.72
			G	191	106		AG	109	60	
							GG	41	23	
1	rs1952234	180486363	A	162	92	0.78	AA	30	18	0.87
			G	276	164		AG	102	56	
							GG	87	54	
1	rs3814326	180504731	C	144	83	0.73	CC	25	13	0.91
			T	300	183		CT	94	57	
							TT	103	63	
1	rs2500111	180535764	C	363	212	0.26	CC	153	88	0.4187
			T	71	52		TC	57	36	

Cluster	SNP Name	Location	Allele Counts			χ^2_{1df}	Genotype Counts			χ^2_{2df}
			AMD	Control	p-value	Test	AMD	Control	p-value	Test
1	rs6424914	180545515	G	409	251	0.44	TT	7	8	
			T	35	17		TG	29	17	0.3967
							TT	3	0	
1	rs4651156	180568689	A	129	65	0.18	AA	18	8	0.3952
			G	299	191		AG	93	49	
							GG	103	71	
1	rs4079923	180578941	A	188	108	0.89	AA	38	26	0.4158
			T	228	134		TA	112	56	
							TT	58	39	
1	rs3814330	180598742	G	319	184	0.81	CC	115	60	0.4336
			T	113	68		TC	89	46	
							TT	12	11	
1	rs6658545	180619259	A	344	205	0.93	AA	130	82	0.1930
			G	104	63		AG	84	41	
							GG	10	11	
1	rs4328036	180626835	A	244	138	0.33	AA	62	39	0.0855
			G	182	120		AG	120	60	
							GG	31	30	
1	rs4650	180628618	C	229	136	0.76	CC	63	42	0.2737
			T	173	108		CT	103	52	
							TT	35	28	
1	rs1053093	180636730	A	103	64	0.90	AA	7	11	0.0436
			G	333	202		AG	89	42	
							GG	122	80	
1	rs3748552	180638582	A	187	113	0.60	AA	37	28	0.3862
			G	243	135		AG	113	57	
							GG	65	39	
1	rs734657	180643976	G	309	193	0.41	GG	108	68	0.5081
			T	131	71		TG	93	57	
							TT	19	7	
1	rs2986551	180654480	C	111	69	0.64	CC	12	13	0.1926

Cluster	SNP Name	Location	Allele Counts			χ^2_{1df}	Genotype Counts			χ^2_{2df}
			AMD	Control	p-value	Test	AMD	Control	p-value	Test
			T	327	187		TC	87	43	
							TT	120	72	
1	rs1887277	180664116	A	305	171	0.27	AA	108	54	0.3309
			C	135	91		AC	89	63	
							CC	23	14	
1	rs2296714	180674607	A	333	183	0.43	AA	126	64	0.4381
			G	109	69		GA	81	35	
							GG	14	7	
1	rs6424920	180704056	C	95	59	0.80	CC	16	7	0.4753
			T	333	197		TC	63	45	
							TT	135	76	
1	rs765225	180747364	C	382	236	0.26	CC	170	107	0.46
			G	52	24		GC	42	22	
							GG	5	1	
1	rs1046934	180755186	A	290	184	0.47	AA	97	67	0.48
			C	146	82		AC	96	50	
							CC	25	16	
1	rs1952256	180766773	C	140	73	0.26	CC	23	13	0.37
			T	286	181		TC	94	47	
							TT	96	67	
1	rs1409811	180779768	C	95	55	0.88	CC	8	4	0.96
			T	351	209		CT	79	47	
							TT	136	81	
1	rs6657374	180784174	A	120	84	0.16	AA	17	12	0.31
			C	326	180		AC	86	60	
							CC	120	60	
2	rs9425343	181395194	A	271	163	0.99	AA	87	52	0.99
			C	165	99		AC	97	59	
							CC	34	20	
2	rs10489579	181875378	A	290	166	0.34	AA	93	52	0.54
			G	150	100		GA	104	62	
							GG	23	19	

Cluster	SNP Name	Location	Allele Counts			χ^2_{1df}	Genotype Counts			χ^2_{2df}
			AMD	Control	p-value	Test	AMD	Control	p-value	Test
2	rs6698109	181903526	A	289	171	0.99	AA	89	55	0.79
			G	161	95		AG	111	61	
							GG	25	17	
2	rs12041704	181972131	A	241	155	0.25	AA	65	47	0.46
			G	203	109		AG	111	61	
							GG	46	24	
3**	rs994970	182429082	A	120	71	0.88	AA	19	8	0.56
			G	328	199		GA	82	55	
							GG	123	72	
3**	rs7544533	182498183	C	311	194	0.45	CC	112	70	0.59
			T	135	74		TC	87	54	
							TT	24	10	
3**	rs1951517	182545155	A	142	79	0.44	AA	24	12	0.75
			G	302	191		AG	94	55	
							GG	104	68	
3**	rs1407431	182558895	A	127	67	0.28	AA	21	8	0.46
			G	305	195		GA	85	51	
							GG	110	72	
3**	rs2057383	182568154	C	138	78	0.34	CC	22	11	0.63
			G	280	186		GC	94	56	
							GG	93	65	
3**	rs1407426	182595392	C	119	72	0.99	CC	20	11	0.94
			T	323	196		TC	79	50	
							TT	122	73	
3**	rs726777	182604480	A	120	72	0.97	AA	20	11	0.95
			T	328	198		AT	80	50	
							TT	124	74	
3**	rs7519247	182643354	A	316	188	0.73	AA	117	68	0.93
			T	114	72		AT	82	52	
							TT	16	10	
3**	rs6688811	182673432	A	229	137	0.92	AA	63	31	0.21
			G	219	133		GA	103	75	

Cluster	SNP Name	Location	Allele Counts		χ^2 at	Genotype Counts		χ^2 at		
			AMD	Control	p-value		AMD	Control	p-value	
3**	rs4650689	182713710	A	202	131	0.39	AA	45	29	0.55
			T	238	135		AT	112	73	
							TT	63	31	
3**	rs743136	182724985	A	238	138	0.48	AA	63	32	0.60
			G	204	132		GA	112	74	
							GG	46	29	
3**	rs6425013	182744486	A	242	135	0.52	AA	64	32	0.70
			G	206	127		AG	114	71	
							GG	46	28	
3**	rs7520459	182756662	A	232	136	0.70	AA	59	32	0.55
			G	212	132		AG	114	72	
							GG	49	30	
3**	rs970578	182770124	A	224	134	0.74	AA	59	29	0.32
			G	216	136		AG	106	76	
							GG	55	30	
3**	rs6425016	182786834	A	226	134	0.73	AA	58	29	0.44
			G	198	124		GA	110	76	
							GG	44	24	
3**	rs1923460	182800254	A	223	134	0.91	AA	57	30	0.46
			G	227	134		GA	109	74	
							GG	59	30	
3**	rs7552781	182807177	C	220	137	0.79	CC	56	30	0.31
			T	226	135		CT	108	77	
							TT	59	29	
3**	rs720972	182817554	A	223	134	0.86	AA	58	29	0.33
			C	217	134		CA	107	76	
							CC	55	29	
3**	rs6659783	182827158	A	295	172	0.48	AA	99	56	0.78
			T	153	100		TA	97	60	
							TT	28	20	
3**	rs721153	182834203	G	142	97	0.27	GG	27	20	0.56

Cluster	SNP Name	Location	Allele Counts		χ^2_{1df}	p-value	Genotype Counts		χ^2_{2df}
			AMD	Control	Test		AMD	Control	Test
			T	300	171		GT	88	57
							TT	106	57
3**	rs1322374	182845982	A	338	194	0.27	AA	130	75
			G	106	74		GA	78	44
							GG	14	15
3**	rs2383457	182868229	C	153	90	0.83	CC	31	11
			T	289	176		CT	91	68
							TT	99	54
3**	rs651967	182896556	C	99	55	0.56	CC	15	7
			T	347	215		CT	69	41
							TT	139	87
3	rs857591	182989175	A	177	105	0.87	AA	34	20
			C	261	159		CA	109	65
							CC	76	47
3	rs1293988	182997950	A	187	114	0.59	AA	41	26
			G	257	144		AG	105	62
							GG	76	41
3	rs2273779	183005651	A	127	80	0.85	AA	22	12
			G	295	180		GA	83	56
							GG	106	62
3	rs7756	183013353	G	286	170	0.51	GG	93	54
			T	154	82		TG	100	62
							TT	27	10
3	rs6657726	183018944	C	291	173	1.0	CC	97	55
			T	153	91		CT	97	63
							TT	28	14
3	rs3766708	183027617	A	153	93	0.79	AA	27	14
			G	287	167		AG	99	65
							GG	94	51
3	rs3817586	183035955	C	389	237	0.86	CC	175	106
			T	53	31		CT	39	25
							TT	7	3

Cluster	SNP Name	Location	Allele Counts		χ^2 at	Genotype Counts		χ^2 at
			AMD	Control	Test	AMD	Control	Test
3	rs2272412	183046606	C 375	205	0.10	CC 163	84	0.2705
			T 61	47		CT 49	37	
						TT 6	5	
3	rs3753565	183048145	A 67	47	0.35	AA 7	5	0.6362
			G 383	221		GA 53	37	
						GG 165	92	
3	rs2178215	183055256	A 255	152	0.70	AA 81	42	0.0892
			C 175	98		AC 93	68	
						CC 41	15	
3	rs2037959	183067550	C 136	83	0.84	CC 22	13	0.9555
			T 310	283		CT 92	57	
						TT 109	63	
3	rs3131550	183085106	C 145	91	0.82	CC 25	13	0.6263
			G 283	171		GC 95	65	
						GG 94	53	
3	rs12084264	183094776	C 311	184	0.99	CC 108	64	0.9997
			G 139	82		GC 95	56	
						GG 22	13	
3	rs7539128	183116764	G 303	179	0.90	GG 108	62	0.8900
			T 131	79		TG 87	55	
						TT 22	12	
3	rs8824	183121960	A 180	101	0.49	AA 44	16	0.0762
			C 254	159		CA 92	69	
						CC 81	45	
3	rs1929092	183128165	A 123	60	0.16	AA 24	10	0.42
			G 311	196		AG 75	40	
						GG 118	78	
3	rs4567244	183135305	A 323	202	0.35	AA 122	79	0.67
			G 121	64		GA 79	44	
						GG 21	10	
3	rs6675505	183138356	C 321	204	0.17	CC 121	80	0.40
			T 125	62		CT 79	44	

Cluster	SNP Name	Location	Allele Counts		χ^2 at	Test	Genotype Counts			χ^2 at
			AMD	Control	p-value			AMD	Control	p-value
3	rs6677914	183154998	C	389	233	0.77	TT	23	9	0.73
			T	59	33		TC	49	25	
						TT	5	4		
3	rs1799957	183163002	G	123	63	0.25	GG	22	9	0.52
			T	323	203		TG	79	45	
						TT	122	79		
3	rs5275	183374715	C	147	89	0.85	CC	28	16	0.91
			T	281	165		TC	91	57	
						TT	95	54		
3	rs3820185	183540000	A	145	80	0.33	AA	27	11	0.47
			C	279	180		CA	91	58	
						CC	94	61		
3	rs2076075	183554941	A	50	37	0.30	AA	3	0	0.10
			G	394	229		GA	44	37	
						GG	175	96		
3	rs7554339	183564551	A	350	228	0.022	AA	142	98	0.069
			T	90	36		TA	66	32	
						TT	12	2		
3	rs1980444	183582617	C	358	215	0.76	CC	146	92	0.096
			T	80	51		TC	66	31	
						TT	7	10		
3	rs7519192	183594076	A	314	180	0.57	AA	114	61	0.59
			G	130	82		GA	86	58	
						GG	22	12		
3	rs1569480	183606118	A	226	128	0.66	AA	62	36	0.78
			G	204	124		AG	102	56	
						GG	51	34		
3	rs6662687	183611548	A	217	131	0.82	AA	55	37	0.65
			G	225	131		AG	107	57	
						GG	59	37		
3	rs4336803	183626059	G	331	204	0.81	GG	130	83	0.64

Cluster	SNP Name	Location	χ^2_{1df}			χ^2_{2df}				
			Allele Counts	Test	p-value	Genotype Counts	Test	p-value		
			T	85	50		TG	71	38	
							TT	7	6	
3	rs1160719	183632124	A	85	49	0.83	AA	11	4	0.63
			G	357	215		GA	63	41	
							GG	147	87	
3	rs4433346	183633970	A	359	218	0.65	AA	147	89	0.66
			G	83	46		GA	65	40	
							GG	9	3	
3	rs6697145	183642248	C	230	137	0.95	CC	62	42	0.39
			T	212	125		CT	106	53	
							TT	53	36	
3	rs4651343	183649644	A	130	81	0.71	AA	23	12	0.62
			C	316	185		AC	84	57	
							CC	116	64	
3	rs1555204	183688872	C	87	57	0.51	CC	9	7	0.79
			T	355	205		CT	69	43	
							TT	143	81	
3	rs2144000	183698899	A	183	126	0.11	AA	39	29	0.26
			G	261	140		GA	105	68	
							GG	78	36	
3	rs6657726	183018944	C	291	173	1.0	CC	97	55	0.72
			T	153	91		CT	97	63	
							TT	28	14	
3	rs3766708	183027617	A	153	93	0.79	AA	27	14	0.66
			G	287	167		AG	99	65	
							GG	94	51	
3	rs3817586	183035955	C	389	237	0.86	CC	175	106	0.86
			T	53	31		CT	39	25	
							TT	7	3	
4	rs6659885	186925883	C	248	145	0.54	CC	78	44	0.84
			G	172	111		CG	92	57	
							GG	40	27	

Cluster	SNP Name	Location	Allele Counts			$\chi^2_{1 df}$	Genotype Counts			$\chi^2_{2 df}$
			AMD	Control	p-value	Test	AMD	Control	p-value	Test
4	rs7513756	186942826	C	184	115	0.60	CC	43	28	0.88
			T	262	151		TC	98	59	
							TT	82	46	
5	rs10921310	189806308	A	322	208	0.090	AA	114	83	0.11
			T	126	60		TA	94	42	
							TT	16	9	
6	rs12138336	193802178	C	408	239	0.80	CC	191	110	0.42
			G	30	19		CG	26	19	
							GG	2	0	
6	rs1998712	192919322	A	360	220	0.51	AA	146	92	0.77
			G	86	46		GA	68	36	
							GG	9	5	
6	rs1925332	192945224	C	334	210	0.39	CC	137	90	0.58
			G	80	42		GC	60	30	
							GG	10	6	
6	rs2477361	192955995	A	356	220	0.34	AA	142	93	0.41
			G	90	46		AG	72	34	
							GG	9	6	
6	rs660711	192967683	A	346	210	0.40	AA	139	89	0.46
			G	86	44		AG	68	32	
							GG	9	6	
6	rs1325299	192978579	C	396	233	0.96	CC	178	107	0.21
			T	42	25		CT	40	19	
							TT	1	3	
6	rs1924757	192991686	A	91	44	0.24	AA	9	6	0.26
			G	353	216		GA	73	32	
							GG	140	92	
6	rs2181948	193013459	A	196	114	0.78	AA	46	26	0.97
			G	250	152		AG	104	62	
							GG	73	45	
6	rs4379659	193048418	C	357	222	0.36	CC	143	94	0.43
			T	89	46		CT	71	34	

Cluster	SNP Name	Location	Allele Counts		Test	Genotype Counts		Test
			AMD	Control		AMD	Control	
6	rs7552975	193071312	A 87	44	0.28	TT 9	6	0.33
			G 349	220		AA 9	6	
						AG 69	32	
6	rs1416962	193186285	A 288	148	0.0089	GG 140	94	0.0018
			G 140	110		GA 88	76	
						GG 26	17	
6	rs3753394	193352574	C 334	192	0.49	CC 122	70	0.56
			T 114	74		TC 90	52	
						TT 12	11	
6	rs800292	193373890	C 368	196	0.0009	CC 160	73	0.0022
			T 60	62		TC 48	50	
						TT 6	6	
6	rs572515	193377918	A 248	90	3.6E-08	AA 71	15	6.8E-07
			G 202	176		AG 106	60	
						GG 48	58	
6	rs1329423	193378044	C 106	68	0.51	CC 13	11	0.65
			T 344	196		TC 80	46	
						TT 132	75	
6	rs3766404	193383489	C 37	49	6.1E-05	CC 3	4	0.0002
			T 409	217		CT 31	41	
						TT 189	88	
6	rs1061147	193385981	A 249	92	5E-08	AA 72	15	8.7E-07
			C 201	176		CA 105	62	
						CC 48	57	
6	rs1061170	193390894	C 249	89	3.7E-08	CC 72	15	7.7E-07
			T 201	173		TC 105	59	
						TT 48	57	
6	rs10922094	193393162	C 198	176	9.6E-09	CC 48	58	2.8E-07
			G 252	90		GC 102	60	
						GG 75	15	
6	rs1292471	193399085	A 201	175	8.4E-08	AA 48	58	1.6E-06

Cluster	SNP Name	Location	χ^2 at Allele Counts			χ^2 at Genotype Counts		
			AMD	Control	p-value	AMD	Control	p-value
			T 245	91		AT 105	59	
						TT 70	16	
6	rs2860102	193399976	A 249	92	5E-08	AA 72	16	1E-06
			T 201	176		TA 105	60	
						TT 48	58	
6	rs2019724	193406574	C 183	164	5.6E-08	CC 39	51	9.7E-07
			T 267	102		TC 105	62	
						TT 81	20	
6	rs10465586	193418986	A 342	150	2.3E-08	AA 136	43	5.7E-07
			T 108	118		TA 70	64	
						TT 15	27	
6	rs3753396	193427399	A 375	221	0.93	AA 153	92	0.48
			G 75	45		AG 69	37	
						GG 3	4	
6	rs403846	193428394	A 261	101	8.9E-08	AA 79	20	1.5E-06
			G 181	163		AG 103	61	
						GG 39	51	
6	rs1065489	193441431	G 372	218	0.98	GG 151	90	0.69
			T 78	46		TG 70	38	
						TT 4	4	
6	rs4230	193532699	G 324	175	0.066	GG 121	56	0.087
			T 124	91		TG 82	63	
						TT 21	14	
6	rs1805287	193542472	C 177	164	3.9E-09	CC 44	55	2E-07
			T 235	82		CT 89	54	
						TT 73	14	
6	rs6428375	193604459	C 341	181	0.012	CC 135	65	0.057
			T 101	83		CT 71	51	
						TT 15	16	
6	rs7417769	193608115	A 102	83	0.0075	AA 15	16	0.0389
			G 346	177		GA 72	51	
						GG 137	63	

Cluster	SNP Name	Location	Allele Counts			χ^2_{1df}	Genotype Counts			χ^2_{2df}
			AMD	Control	p-value	Test	AMD	Control	p-value	Test
6	rs1853883	193613257	C	267	113	5E-06	CC	86	27	9.7E-05
			G	177	153		CG	95	59	
							GG	41	47	
6	rs379370	193615850	C	327	160	0.0004	CC	117	49	0.0012
			T	121	106		TC	93	62	
							TT	14	22	
6	rs1971579	193618858	A	338	179	0.034	AA	129	62	0.054
			C	88	69		AC	80	55	
							CC	4	7	
6	rs3915683	193618931	A	67	42	0.80	AA	7	4	0.93
			G	361	226		GA	53	34	
							GG	164	96	
6	rs4915318	193628745	A	74	69	0.0024	AA	9	10	0.012
			C	374	197		AC	56	49	
							CC	159	74	
6	rs3790414	193651956	A	72	67	0.0025	AA	9	9	0.0096
			T	376	197		TA	54	49	
							TT	161	74	
6	rs7531555	193660967	C	362	194	0.0057	CC	155	74	0.023
			T	70	64		TC	52	46	
							TT	9	9	
6	rs6428379	193669193	C	178	149	3.8E-05	CC	41	46	0.0005
			T	262	115		TC	96	57	
							TT	83	29	
6	rs10922152	193694663	A	279	137	0.0059	AA	86	36	0.0223
			T	171	129		TA	107	65	
							TT	32	32	
6	rs2336595	193732133	A	24	32	0.0016	AA	2	1	0.0019
			G	422	236		AG	20	30	
							GG	201	103	
6	rs698859	193740022	A	198	110	0.43	AA	49	20	0.2076
			G	248	156		AG	100	70	

Cluster	SNP Name	Location	Allele Counts			$\chi^2_{1 df}$	Genotype Counts			$\chi^2_{2 df}$
			AMD	Control	p-value	Test	AMD	Control	p-value	Test
6	rs5998	193741455	C	224	126	0.44	GG	74	43	
			T	224	142		CC	56	28	0.6709
							TC	112	70	
6	rs1615413	193761974	A	222	141	0.43	TT	56	36	
			G	226	127		AA	54	36	0.7197
							GA	114	69	
6	rs6003	193762678	A	423	231	0.0029	GG	56	29	
			G	25	31		AA	201	101	0.0038
							AG	21	29	
6	rs6428381	193770290	A	26	33	0.0022	GG	2	1	
			C	418	233		AA	2	1	0.0028
							AC	22	31	
6	rs3762271	193802099	A	198	112	0.56	CC	198	101	
			C	252	156		AA	48	20	0.2076
							CA	102	72	
6	rs4915327	193820650	C	402	228	0.0021	CC	75	42	
			T	22	30		CC	191	100	0.0061
							TC	20	28	
6	rs12116571	193820650	C	364	244	0.0002	TT	1	1	
			T	68	16		CC	151	114	0.0006
							CT	62	16	
6	rs10732295	193868302	C	409	233	0.002	TT	3	0	
			T	25	33		CC	194	101	0.0023
							TC	21	31	
6	rs10429911	193877801	A	22	28	0.0072	TT	2	1	
			C	388	226		AA	2	1	0.0094
							AC	18	26	
6	rs10737688	193887712	C	228	131	0.79	CC	185	100	
			T	212	127		CC	54	32	0.856
							TC	120	67	
6	rs10922181	193897709	C	169	102	0.93	TT	46	30	
							CC	35	14	0.105

Cluster	SNP Name	Location	Allele Counts		χ^2 or	Genotype Counts			χ^2 or	
			AMD	Control	Test		AMD	Control	Test	
6	rs489839	193970506	G	279	166		CG	99	74	0.5855
							GG	90	46	
			C	341	204	0.69	CC	134	79	
6	rs7548481	193979471	G	101	56		CG	73	46	0.43
							GG	14	5	
			A	274	159	0.92	AA	88	47	
6	rs7418217	194003905	G	170	97		AG	98	65	0.39
							GG	36	16	
			T	275	165	0.98	TG	99	69	
6	rs1764622	194013736					TT	53	48	0.84
			C	285	176	0.81	CC	94	57	
			T	155	92		TC	97	62	
6	rs570845	194024406					TT	29	15	0.92
			A	290	176	0.86	AA	95	57	
			T	156	92		AT	100	62	
6	rs2786104	194044091					TT	28	15	0.63
			A	37	27	0.42	AA	2	1	
			T	405	239		TA	33	25	
6	rs10922213	194083923					TT	186	107	0.92
			C	301	178	0.94	CC	99	57	
			T	147	88		TC	103	64	
6	rs10922216	194103855					TT	22	12	0.74
			A	288	171	0.76	AA	98	55	
			C	136	85		AC	92	61	
6	rs2821121	194113713					CC	22	12	0.97
			C	295	174	0.96	CC	96	56	
			T	147	86		TC	103	62	
6	rs4915545	194143686					TT	22	12	0.59
			C	242	141	0.96	CC	63	33	
			T	196	115		TC	116	75	
							TT	40	20	

Cluster	SNP Name	Location	Allele Counts		χ^2 at	Test	Genotype Counts		χ^2 at	
			AMD	Control	p-value		AMD	Control	p-value	
6	rs10922234	194167696	A	353	212	0.95	AA	139	86	0.62
			G	91	54		AG	75	40	
							GG	8	7	
6	rs10922237	194178359	G	237	150	0.44	GG	59	38	0.64
			T	203	114		TG	119	74	
							TT	42	20	
6	rs10801614	194251930	C	355	216	0.56	CC	142	91	0.40
			T	85	46		TC	71	34	
							TT	7	6	
6	rs7516153	194273380	C	198	122	0.70	CC	41	24	0.76
			T	238	138		CT	116	74	
							TT	61	32	
6	rs4915555	194283171	C	342	209	0.88	CC	135	86	0.43
			G	86	51		GC	72	37	
							GG	7	7	
6	rs6676795	194302896	C	84	50	0.88	CC	6	7	0.28
			G	336	206		CG	72	36	
							GG	132	85	
6	rs12116508	194312109	C	93	52	0.77	CC	7	8	0.17
			T	345	204		TC	79	36	
							TT	133	84	
6	rs10801620	194323063	A	205	125	0.79	AA	44	25	0.76
			C	241	141		CA	117	75	
							CC	62	33	
6	rs12127378	194332749	C	93	52	0.70	CC	6	8	0.085
			T	345	208		TC	81	36	
							TT	132	86	
6	rs9427669	194351589	C	349	212	0.73	CC	134	87	0.17
			T	95	54		TC	81	38	
							TT	7	8	
6	rs2488389	194362798	C	331	200	0.39	CC	123	77	0.67
			T	109	56		TC	85	46	

Cluster	SNP Name	Location	Allele Counts		χ^2 df		Genotype Counts		χ^2 df	
			AMD	Control	p-value	Test	AMD	Control	p-value	Test
							TT	12	5	
6	rs2488410	194382162	A 93	50	0.66		AA	7	8	0.12
			G 341	200			AG	79	34	
							GG	131	83	
6	rs1891497	194391212	A 91	54	0.92		AA	6	8	0.15
			G 347	210			AG	79	38	
							GG	134	86	
6	rs1747815	194429760	A 70	39	0.91		AA	6	6	0.40
			G 334	191			GA	58	27	
							GG	138	82	
6	rs7533766	194439771	A 180	116	0.53		AA	34	24	0.66
			G 254	140			GA	112	68	
							GG	71	36	
6	rs1998598	194459299	A 312	179	0.59		AA	110	61	0.86
			G 132	83			AG	92	57	
							GG	20	13	
6	rs9427953	194490552	C 337	210	0.94		CC	137	88	0.55
			T 75	46			CT	63	34	
							TT	6	6	
6	rs10922288	194501197	C 99	52	0.44		CC	9	6	0.52
			T 351	214			TC	81	40	
							TT	135	87	
6	rs6704186	194525344	C 88	51	0.75		CC	5	6	0.28
			T 332	205			TC	78	39	
							TT	127	83	
6	rs10922324	194599062	A 352	217	0.67		AA	142	88	0.85
			T 90	51			TA	68	41	
							TT	11	5	
6	rs10754236	194609145	C 281	155	0.18		CC	88	43	0.37
			T 163	111			TC	105	69	
							TT	29	21	
6	rs10494762	194619495	C 94	66	0.29		CC	9	9	0.48

Cluster	SNP Name	Location	Allele Counts			χ^2 df	Genotype Counts			χ^2 df
			AMD	Control	p-value		AMD	Control	p-value	
			G 346	200			CG 76	48		
							GG 135	76		
6	rs10801633	194629153	C 241	121	0.032		CC 74	32	0.15	
			T 201	141			TC 93	57		
							TT 54	42		
6	rs6671069	194644758	C 259	142	0.24		CC 80	44	0.37	
			T 185	122			TC 99	54		
							TT 43	34		

*The number of SNPs successfully genotyped in clusters 1, 2, 3, 4, 5, and 6 were 82, 4, 61, 2, 1, and 86. All SNPs reported in this manuscript are included in this table.

**Two asterisks in the "Cluster" column denote SNPs within the Fibulin 6 locus referred to in the text.

Table 5. Genotyping in the replication sample; allele and genotype association between AMD and 14 polymorphic SNPs in the RCA locus.

Cluster	SNP Name	Location	Allele Counts		χ^2 or Test		Genotype Counts		χ^2 or Test	
			AMD	Control	p-value		AMD	Control	p-value	
6	rs3753394	193352574	C	240	93	0.97	CC	86	33	0.99
			T	110	43		TC	68	27	
							TT	21	8	
6	rs800292	193373890	A	43	23	0.15	AA	1	4	0.030
			G	309	111		AG	41	15	
							GG	134	48	
6	rs1061170	193390894	C	185	46	0.0039	CC	52	11	0.014
			T	155	72		TC	81	24	
							TT	37	24	
6	rs2019724	193406574	C	138	75	0.0020	CC	29	23	0.0082
			T	210	61		TC	80	29	
							TT	65	16	
6	rs1065489	193441431	G	290	108	0.38	GG	123	43	0.52
			T	60	28		TG	44	22	
							TT	8	3	
6	rs4230	193532699	G	257	89	0.099	GG	93	32	0.081
			T	95	47		TG	71	25	
							TT	12	11	
6	rs7417769	193608115	A	76	43	0.010	AA	10	8	0.047
			G	274	87		GA	56	27	
							GG	109	30	
6	rs379370	193615850	C	254	82	0.026	CC	94	28	0.074
			T	96	50		TC	66	26	
							TT	15	12	
6	rs3915683	193618931	A	54	28	0.16	AA	7	3	0.28
			G	298	108		GA	40	22	
							GG	129	43	
6	rs3790414	193651956	A	57	25	0.58	AA	3	4	0.20
			T	293	111		TA	51	17	
							TT	121	47	

Cluster	SNP Name	Location	Allele Counts			χ^2_{1df}	Genotype Counts			χ^2_{2df}
			AMD	Control	p-value		AMD	Control	p-value	
6	rs10922152	193694663	A	226	71	0.015	AA	74	16	0.026
			T	126	65		TA	78	39	
							TT	24	13	
6	rs5998	193741455	C	160	66	0.54	CC	38	14	0.46
			T	192	70		TC	84	38	
							TT	54	16	
6	rs6003	193762678	A	332	123	0.074	AA	157	57	0.057
			G	18	13		AG	18	9	
							GG	0	2	
6	rs3762271	193802099	A	173	55	0.084	AA	46	11	0.22
			C	179	81		CA	81	53	
							CC	49	24	

TABLE 6: SEQUENCES

Sequence Name and SEQ ID NO:	Sequence
RS1061170-1277F (SEQ ID NO:3)	5' CTTTATTTATTTATCATTGTTAT GGTCCTTAGGAAAATGTTATTT 3'
RS1061170-1277R (SEQ ID NO:4)	5' GGCAGGCAACGTCATAGA TTTACC 3'
RS106117077V2 (SEQ ID NO:5)	5' TTTCTTCCATGATTTTG 3'
RS1061170-1277M2 (SEQ ID NO:6)	5' TTCTTCCATAATTTTG 3'
Rs1061170 (short) (SEQ ID NO:7)	5' AAAATGGATATAATCAAAATTAT GAAGAAAGTTTGTACAG 3'
Rs1061170 (long) (SEQ ID NO:8)	5' CTGGGATCACATTCATTGCACACAA GATGGATGGTCGCCAGCAGTACCA TGCCTCAGAAAATGTTATTTTCCTTATT TGGAAAATGGATATAATCAAAATTAT GGAAGAAAGTTTGTACAGGGTAAAT CTATAGACGTTGCCTGCCATCCTGG CTACGCTCTTCCAAAAGCGCAGAC CACAGTTACATGTATGGAGAATGG 3'

References

1. R. Klein, B. E. Klein, S. C. Tomany, S. M. Meuer, G. H. Huang, *Ophthalmology* 109, 1767 (2002).
2. R. Klein, T. Peto, A. Bird, M. R. Vannewkirk, *Am. J. Ophthalmol.* 137, 486 (2004).
3. G. R. Abecasis *et al.*, *Am. J. Hum. Genet.* 74, 482 (2004).
4. S. K. Iyengar *et al.*, *Am. J. Hum. Genet.* 74, 20 (2004).
5. M. L. Klein *et al.*, *Arch. Ophthalmol.* 116, 1082 (1998).
6. J. Majewski *et al.*, *Am. J. Hum. Genet.* 73, 540 (2003).
7. J. H. Schick *et al.*, *Am. J. Hum. Genet.* 72, 1412 (2003).
8. J. M. Seddon, S. L. Santangelo, K. Book, S. Chong, J. Cotc, *Am. J. Hum. Genet.* 73, 780 (2003).
9. D. E. Weeks *et al.*, *Am. J. Hum. Genet.* 75, 174 (2004).
10. Materials and methods are described above.
11. D. W. Schultz *et al.*, *Hum. Mol. Genet.* 12, 3315 (2003).
12. D. J. Schaid, C. M. Rowland, D. E. Tines, R. M. Jacobson, G. A. Poland, *Am. J. Hum. Genet.* 70, 425 (2002).
13. H. Zhao, R. Pfeiffer, M. H. Gail, *Pharmacogenomics* 4, 171 (2003).
14. J. Acosta, X. Qin, J. Halperin, *Curr. Pharm. Des.* 10, 203 (2004).
15. H. J. Muller-Eberhard, R. D. Schreiber, *Adv. Immunol.* 29, 1 (1980).
16. R. F. Mullins, S. R. Russell, D. H. Anderson, G. S. Hageman, *FASEB J.* 14, 835 (2000).
17. L. V. Johnson, W. P. Leitner, M. K. Staples, D. H. Anderson, *Exp. Eye. Res.* 73, 887 (2001).
18. E. Giannakis *et al.*, *Eur. J. Immunol.* 33, 962 (2003).
19. J. M. Seddon, G. Gensler, R. C. Milton, M. L. Klein, N. Rifai, *JAMA* 291, 704 (2004).
20. C. Mold, H. Gewurz, T. W. Du Clos, *Immunopharmacology* 42, 23 (1999).

21. J. M. Seddon, J. Cote, N. Davis, B. Rosner, *Arch. Ophthalmol.* 121, 785 (2003).
22. J. Esparza-Gordillo *et al.*, *Immunogenetics* 56, 77 (2004).
23. J. R. Greenfield *et al.*, *Circulation* 109, 3022 (2004).
24. J. M. Backes, P. A. Howard, P. M. Moriarty, *Ann. Pharmacother.* 38, 110 (2004).
25. M. H. Wener, P. R. Daum, G. M. McQuillan, *J. Rheumatol.* 27, 2351 (2000).
26. R. F. Mullins, N. Aptsiauri, G. S. Hageman, *Eye* 15, 390 (2001).
27. M. A. Dragon-Durey *et al.*, *J. Am. Soc. Nephrol.* 15, 787 (2004).
28. D. S. Friedman *et al.*, *Arch. Ophthalmol.* 122, 564 (2004).
29. J. C. Barrett, B. Ery, L. Maller, M. J. Daly, *Bioinformatics* 21, 263 (2005).
- S1. R. Klein *et al.*, *Ophthalmology* 98, 1128 (1991).
- S2. M. L. Klein *et al.*, *Arch. Ophthalmol.* 116, 1082 (1998).
- S3. R. Klein, B. E. Klein, S. C. Jensen, S. M. Meuer, *Ophthalmology* 104, 7 (1997).
- S4. J. Majewski *et al.*, *Am. J. Hum. Genet.* 73, 540 (2003).
- S5. R. Klein, B. E. Klein, K. L. Linton, *Ophthalmology* 99, 933 (1992).
- S6. R. Klein, B. E. Klein, S. C. Tomany, S. M. Meuer, G. H. Huang, *Ophthalmology* 109, 1767 (2002).
- S7. K. J. Livak, *Genet. Anal.* 14, 143 (1999).
- S8. J. B. de Kok, E. T. Wiegerinck, B. A. Giesendorf, D. W. Swinkels, *Hum. Mutat.* 19, 554 (2002).
- S9. A. Bansal *et al.*, *Proc. Natl. Acad. Sci. USA* 99, 16871 (2002).
- S10. J. Dausset *et al.*, *Genomics* 6, 575 (1990).
- S11. K. H. Buetow *et al.*, *Proc. Natl. Acad. Sci. USA* 98, 581 (2001).
- S12. K. L. Mohlke *et al.*, *Proc. Natl. Acad. Sci. USA* 99, 16928 (2002).
- S13. M. R. Nelson *et al.*, *Genome Res.* 14, 1664 (2004).
- S14. C. Jurinke, P. Oeth, D. van den Boom, *Mol. Biotechnol.* 26, 147 (2004).

- S15. D. Thomas, *Statistical methods in genetic epidemiology* (Oxford University Press, New York, 2004), pp. page 52.
- S16. J. C. Barrett, B. Fry, J. Mailer, M. J. Daly, *Bioinformatics* 21, 263 (2005).
- S17. S. B. Gabriel *et al.*, *Science* 296, 2225 (2002).
- S18. *Nature* 426, 789 (2003). Page 32
- S19. D. W. Schultz *et al.*, *Hum. Mol. Genet.* 12, 3315 (2003).
- S20. G. R. Abecasis *et al.*, *Am. J. Hum. Genet.* 74, 482 (2004).
- S21. M. Hayashi *et al.*, *Ophthalmic. Genet.* 25, 111 (2004).
- S22. S. K. Iyengar *et al.*, *Am. J. Hum. Genet.* 74, 20 (2004).
- S23. G. J. McKay *et al.*, *Mol. Vis.* 10, 682 (2004).
- S24. E. M. Stone *et al.*, *N. Engl. J. Med.* 351, 346 (2004).

All references described herein are incorporated by reference in their entirety.

We claim:

1. A method for determining whether or not an individual has an increased risk of susceptibility to age-related macular degeneration (AMD) comprising:
 - i. obtaining a biological sample from an individual;
 - ii. analyzing the biological specimen to determine whether a human complement factor H (CFH) has at least one mutation and/or polymorphism in the human CFH gene or gene product as compared to a control group, wherein the presence of a mutation and/or polymorphism indicates that the individual is at increased risk of developing AMD.
2. The method of claim 1, wherein the mutation and/or polymorphism is in a coding region of the *CFH* gene.
3. The method of claim 2, wherein the mutation and/or polymorphism results in an amino acid change in the expression product.
4. The method of claim 1, 2, or 3, wherein the mutation and/or polymorphism is within a region of *CFH* encoding a short consensus repeat (SCR).
5. The method of claim 4, wherein the SCR is SCR7.
6. The method of claim 5, wherein the mutation and/or polymorphism encodes amino acid 402 of complement factor H (CFH).
7. The method of claim 6, wherein the mutation and/or polymorphism changes the tyrosine at amino acid 402 to a histidine.
8. The method of claim 1, wherein the mutation and/or polymorphism changes the thymine at position 1277 of SEQ ID NO. 1 to a cytosine.
9. The method of claim 1, wherein the individual is Caucasian and at least 55 years of age.

10. The method of claim 1, further comprising administering an AMD treatment to the individual if the presence of a mutation and/or polymorphism is detected.
11. The method of claim 10, wherein the treatment is selected from the group consisting of an angiogenesis inhibitor, a VEGF inhibitor, photodynamic laser therapy, and pegaptanib sodium.
12. The method of claim 11, wherein the VEGF inhibitor is ranibizumab.
13. A method of screening for an individual at increased risk of developing an eye disease, comprising:
 - i. obtaining a biological sample from a subject;
 - ii. analyzing human complement factor H (CFH) to determine if more mutations and/or polymorphisms in the human CFH gene or gene product in the biological sample are present when compared to a control group, wherein the presence of a mutation and/or polymorphism indicates that the individual is at increased risk of developing AMD.
14. The method of claim 14, wherein the eye disease is an on optic nerve disorder.

1/10





FIG. 1

2/10



3/10




FIG. 3

4/10

SEQUENCE ID NO:1
HOMO SAPIENS COMPLEMENT FACTOR H (CFH)

1	aattcttggga	agaggagaaac	tggacgttgt	gaacagagtt	agctggtaaa	tgtcctctta
61	aaagatccaa	aaaatggagac	ttctagcaaa	gattatttgc	cttatgttat	gggctatttg
121	tgtagcagaa	gattgcaatg	aacttctcc	aagaagaaat	acagaaatc	tgcacagttc
181	ctggctgac	caaacatc	cagaaggcac	ccaggctatc	tataaatgcc	gccctggata
241	tagatctctt	ggaaatgtaa	taattggtatg	caggaaaggga	gaatgggttg	ctcttaatcc
301	attaagga	gttcagaaaa	ggcctgtg	acatcctgga	gatactcctt	ttggtacttt
361	tacccttaca	ggaggaatg	tgtttgaata	tgggtgaaaa	gcgtgtata	catgtaatga
421	ggggtatcaa	ttgctagggtg	agattaatta	ccgtgaatgt	gacacagatg	gatggacca
481	tgatattcct	ataigtgaag	ttgtgaagt	tttaccagt	acagcaccag	agaatggaaa
541	aattgtcagt	agtgcgaatg	aaccagatcg	ggaataccat	tttggacaag	cagtacggtt
601	tgtatgtaac	tcaggctaca	agattgaagg	agatgaagaa	atgcattgtt	cagacgatgg
661	tttttggagt	aaagagaac	caaagtgtgt	ggaaatttca	tgcaaatccc	cagatgttat
721	aaatggatct	ctctatctc	agaagattat	ttataaggag	aatgaacgat	ttcaatataa
781	atgtaacatg	ggttatgaat	acagtgaag	aggagatgct	glatgcactg	aatctggatg
841	gcgtccgctt	cttctcatgt	aagaaaaatc	tgtgtgataat	cttbatatc	caaatgggtga
901	ctactcacct	ttaaggatta	aacacagaac	ttggagatgaa	atcacgtacc	agtgtagaaa
961	tggtttttat	cctgcaaccc	ggggaaatac	agccaaatgc	acaagtactg	gctggatacc
1021	tgtcccgaga	tgtactctga	aaccttgtga	tattccagac	attaaacatg	gaggtctata
1081	tcattgagatt	atgcgtgagac	catactttcc	agtagctgta	ggaaaaatc	actcctatta
1141	ctgtgatgaa	cattttgaga	ctccgtcagg	aagtactcgg	gatcacattc	attgcacaca
1201	agatggatgg	tcgcagcag	taccatgcct	cagaaaaatg	tattttcctt	atttggaaaa
1261	tggatataat	caaaaatgat	gaagaaagt	tgtacagggt	aaatctatag	acgttgccctg
1321	ccatcctggc	tacgctcttc	caaaaagcga	gaccacagt	acatgtatgg	agaatggcgtg
1381	gtctcctact	cccagatgca	tccgtgtcaa	aacatgttcc	aaatcaagta	tagatattga
1441	gaatgggttt	attttctgaat	ctcagtatac	atatgcctta	aagaaaaag	cgaatatca
1501	atgcaaaacta	ggatatgtaa	cagcagatgg	tgaacaatca	ggatcaatta	gatgtgggaa
1561	agatggatgg	tcagctcaac	ccacgtgcac	taaatcttgt	gatattccag	tatttatgaa
1621	tgcagaaact	aaaaatgact	tcacatggtt	taagctgaat	gacacattgg	actatgaatg
1681	ccatgatgggt	tatgaaagca	atactggaag	caccactgtg	tcctatgtgt	gtgggtacaa
1741	tggttggtct	gatttaacca	tatgttatga	aagagaatgc	gaacttccta	aaatagatgt
1801	acacttagtt	cctgatcgca	agaaagacca	gtataaaagt	ggagagggtg	tgaattcttc
1861	ctgcaaaaca	ggatttacaa	tagttggacc	taattccgtt	cagtgctacc	actltggatt
1921	gtctcctgac	ctcccaatat	gtaaaagaca	agtacaatca	tgtggtccac	ctcctgaact
1981	cctcaatggg	aatgttaagg	aaaaaacgaa	agaagaatat	ggacacagtg	aagtgtgtga
2041	atatttatgtc	aatcctagat	ttctaagtaa	gggacctaat	aaaattcaat	gtgttgatgg
2101	agagtggaca	actttaccag	tgtgtattgt	ggaggagagt	acctgtggag	atatacctga
2161	acttgaacat	ggctggggcc	agctttcttc	ccctcttatt	tactatggag	atbcagttga
2221	attcaattgc	tcagaatcat	ttacaatgat	tggacacaga	ctcaattacgt	gtgttgatgg
2281	agtatggacc	caactcccc	agtgtgtggc	aatagataaa	cttaagaagt	gcaaatcac
2341	aaatttaatt	atacttgagg	aacatttaaa	aaacaagaag	gaattcgatc	ataattctaa
2401	cataaggtga	agatgtagag	gaaaagaagg	atggatacac	acagctctga	taattggagg
2461	atgggatcca	gaagtgaact	gctcaatggc	acaaatacaa	ttatgccccc	ctccacctca
2521	gattcccaat	ctctacaata	tgacaaccac	actgaattat	cggaatggag	aaaaagtatc
2581	tgttcttttg	caagaaaatt	actcaattca	ggaaggagaa	gaattatcat	gcaaatagtg
2641	aagatggcag	tcaataccac	tctgtgttga	aaaaattcca	tgttcacac	cactcagat
2701	agaacacgga	accatttaatt	catccaggtc	ttcacaagaa	agttatgcac	atgggactaa

FIG. 4

SUBSTITUTE SHEET (RULE 26)

5/10

```

2761 attgagttat acttgtagg gtggtttcag gatatctgaa gaaatgaaa caacatgcta
2821 catgggaaaa tggagttctc cacctcagtg tgaaggcctt ccttgtaaat ctccacctga
2881 gattttctcat ggtgtgttag ctcacatgtc agacagttat cagtatggag aagaagttac
2941 gtacaaaatgt tttgaagggt ttggaattga tgggcctgca attgcaaaat gottaggaga
3001 aaaatggctct caccctccat catgcataaa aacagattgt ctgagtttac ctgagcttga
3061 aaatgccata cccatgggag agaagaagga tgtgtataag gcggtgagc aagtgaactta
3121 cacttgtagca acatattaca aaatggatgg agccagtaat gtaacatgca ttaatagcag
3181 atggacagga aggccaaat gcagagacac ctctgtgtg aatccgccca cagtacaaaa
3241 tgcttatata gtgtcgagac agatgagtaa atatccatct ggtgagagag tacgttatca
3301 atgtaggagc ccttatgaaa tgtttgggga tgaagaagtg atgtgttaa atggaaactg
3361 gacggaacca cctcaatgca aagattctac aggaaaatgt gggccccctc cacctattga
3421 caatgggagc attacttcat tccggtgtc agtatatgct ccagcttcat cagttgagta
3481 ccaatgccag aacttgtagc aacttgagg taacaagcga ataacatgta gaaatggaca
3541 atggtcagaa ccacaaaaat gcttacatcc gtgtgtaata tcccgagaaa ttatggaaaa
3601 ttataacata gcattaaggt ggacagccaa acagaagctt tattcgagaa caggtgaatc
3661 agttgaatgt gtgtgtaaac ggggatatcg tctttcatca cgttctcaca cattgcgaac
3721 aacatgtttg gatgggaaac tggagtatcc aacttgtagc aaaagataga atcaatcata
3781 aagtgcacac ctttattcag aactttagta ttaaatcagt tctcaatttc attttttatg
3841 tattgtttta ctctttttta ttcatacgtt aaattttgga ttaattttgtg aaaatgtaat
3901 tataagctga gaccgtggc tctctt (SEQ ID NO. 1)

```

FIG. 4 (cont.)

6/10

SEQUENCE ID NO:2
HUMAN COMPLEMENT FACTOR H

```

1  mrllakiicl mlwaicvaed cnelpprrnt eiltgswsdq typegtqaiy kcrpgyrslg
61  nvimvcrkge wvalnplrkc qkrpcghpgd tpfgtftltg gnvfeygvka vytcneqyql
121 lgeinyrecd tdgwtndipi cevkvclpvt apengkivss amepdreyhf qqavrfvcns
181 gykiegdeem hcsddgfswk ekpkcveisc kspdvingsp isqkiiyken erfgykcnmg
241 yeysergdav ctesgwrplp sceekscdnp yipngdyspl rikhrtgdei tyqcrngfyp
301 atrgntakct stgwaparc tlkpcdypdi khgglyhenm rrpypfvavg kyysyycdeh
361 fetpsgsywd hihctqdgws pavpcrlrky fpylengynq nygrkfvqgk sidvachpgy
421 alpkaqtvtv cmengwsptp rcirvktcsk ssidiengfi sesqytyalk ekakyqcklg
481 yvtadgetsq sircgkdgws acptcikscd ipvfmmartk ndftwfklnl tldyechdgy
541 esntgsttgs ivcgyngwsd lpicyerece lpkidvhlvp drkkdqykvq evlkfscckpg
601 ftivgpnsvq cyhfglspdl pickéqvqsc gpppellngn vkektkeeyg hsevvyyyn
661 prflmkgnk iqcvdgewtt lpvciveest cgdipelehq waqlsspppy ygdsvefncs
721 esftmighrs itcihgwtvq lpqcvaiddl kkckssnlii leehlknkke fdhnsniryr
781 crgkegwihv vcingrwdpe vnscmaqiql cppppqipns hnmттtlinyr dgekvsvlcq
841 enyliqegeee itckdgrwqs iplcvekipt sqppqiehgт insrrssqes yahgtklsyt
901 ceggfrisee nettcmgkw sppqceglp cksppeishg vvahtmsdsyq yqeevtykcf
961 egfgidgpai akclgekwsh ppsciktdcl slpsfenaip mgekkdvya geqvtytcat
1021 yykmdgasnv tcinsrwtgr pterdtscvn pptvqnayiv srqmskypsg ervryqcrsp
1081 yemfgdeevm clngnwtepp gckdstgkcg ppppidngdi tsfplsyyap assveygcqn
1141 lyqlegnkri tcrngqwsep pkclhpcvis reimenynia lrwtakqkly srtgesvefv
1201 ckrgyrlssr shtlrттcwd gkleypctak r (SEQ ID NO. 2)

```

FIG. 5

7/10

FIGURE SCR7 ALIGNMENT (MANUAL ADJUSTMENT AFTER CLUSTALW ALIGNMENT)

Mus musculus	349	VKKCVKFWVEGDSA- WKKVVVQSLKACVNGSLQNCQTATTCENGSSPPICI	(SEQ ID NO: 11)
Rattus norvegicus	349	IQCCTHWVEGSL-WRRRIQSKACCHSGSLNCGDTHLCENGSSPPICV	(SEQ ID NO: 12)
Homo sapiens	386	LAKCFPMLENGNW-GRKFVGSISIDACHFAPLPAKITVTCHENGSTPCCI	(SEQ ID NO: 13)
Gallus gallus	390	LTRGVGP-ENGLIONNW-RYKESEPT-FVKNNRT-NETGETTCS-AGHSTPPII	(SEQ ID NO: 14)

FIG. 6

8/10

SEQUENCE ID NO.9
 GENBANK ACCESSION NO. NM000186
 HOMO SAPIENS COMPLEMENT FACTOR H (CFH)

FIG. 7

1	aattcttggga	agaggagaac	tggacgttgt	gaacagaggtt	agctgggtaaa	tgtccctctta
61	aaagatccaa	aaaatgagac	ttctagcaga	gattattttgc	cttatgtttat	gggctatttgc
121	tgtagcagaa	gatttgaactg	aacttcctcc	aagaagaatat	acagaaatc	tgacaggttc
181	ctggctcagc	caaacatctc	cagaaggcac	ccaggctatc	tataaatgcc	gccctggata
241	tagactcctt	ggaaatgtaa	taattgttatg	caggaaggga	gaatgggttg	ctcttaatcc
301	attaaggaaa	tgtcagaaaa	ggccctgtgg	acatccttga	gatactcctt	ttgtgtacttt
361	tacoccttaca	ggaggaaatg	tgtttgaata	tgggtgtaaaa	gctgtgtata	catgtaatga
421	gggggtatcaa	ttgtcagggtg	agattaattta	ccgtgaatgt	gacacagtag	gatggaccac
481	tgtatattcct	atatgtgaag	ttgtgaagtg	tttaccagtg	acagcaccag	agaattggaaa
541	aattgtcagt	agtgcaatgg	aaccagatcg	ggaataccat	tttggacaag	cagtcacgttg
601	tgtatgtaac	tcaggctaca	agattgaagg	agatgaagaa	atgcattgtt	cagacagtgg
661	tttttggagt	aaagagaacc	caaagtgtgt	ggaaatttca	tgcacatccc	cagatgttat
721	aaatggatct	cctatatctc	agaagattat	ttataaggag	aatgaacgat	ttcaatatata
781	atgtaacatg	ggtttatgaat	acagtgaagg	aggagatgct	gtatgcactg	aatctggatg
841	gcgtccgttg	ccttcacgtg	aagaaaaatc	atgtgtataat	ccttatattc	caaatgggtga
901	ctactcacct	ttaaggattta	aacacagaa	tggagatgaa	atcacgtacc	agtgtagaaa
961	tggttttttat	cctgcacacc	ggggaaatac	agccaaatgc	acaagtactg	gctggatacc
1021	tgtcccgagta	tgtaccttga	aacctgtgtga	ttatccagac	atataacatg	gaggtctata
1081	tcatgagaat	atcgttagac	catactttcc	agtagctgtga	gtgaaatatt	actcctattt
1141	ctgtgatgaa	cattttgaga	ctccgtcagg	aagttaactgg	gatcacatc	attgcacaca
1201	agatggatgg	tcggccagcag	taccatgcct	cagaaaaatg	tattttccct	atttggaaaa
1261	tggatatcaat	caaatgatg	gaagaaagtt	tgtacagggt	aaatctratag	acgttccctg
1321	ccatccctggc	tacgctcttc	caaaagcgca	gaccacagtt	acatgtatgg	agaatggctg
1381	gtctccctact	cccagatgca	tcctgtgcaa	aacatgttcc	aaatcaagta	tagatatgtga
1441	gaatcgggttt	attcttgaat	ctcagtatac	atatgcocta	aaagaaatga	cgaatattca
1501	atgcacaaata	ggatatgtaa	cagcagatgg	tgaacatca	ggatcaatta	gatgtgggaa
1561	agatggatgg	tcagctcaac	ccacgtgcac	taaaatttgt	gataccocag	tatttatgaa
1621	tgcaggaact	aaaaatgact	tcacatggtt	taagctgaat	gacacattgg	actatgaatg
1681	ccatgatggt	tattgaagca	atactggaag	caccactggg	tccatagtgt	tgtggtacaa
1741	tggttggtct	gatctaccac	tatgtttatga	aagagaatgc	gaacttctca	aaatagatgt
1801	acacttagtt	cctgatcgca	agaaagacca	gtataaaagt	ggagaggtgt	tgaattcttc
1861	ctgcacaaaca	ggattttacaa	tagttggacc	taattccgtt	cagtgctacc	actttggatt
1921	gtctcctgac	ctcccaatat	gtaaaagaca	agtaacaatca	tgtgtgtccac	ctctggaact
1981	cctcaatggg	aattgttaagg	aaaaaacgaa	agaagaatat	ggacacagtg	aagtgttgga
2041	atattattggc	aatcctagat	ttctaattgaa	gggacctaata	aaaattcaat	gtatgtatgg
2101	agagtggaca	actttaccag	tgtgtattgt	ggaggagagt	acctgtggag	ataactctga
2161	acttgaacat	ggctggggccc	agctttcttc	ccctccttat	tactatggag	attcagtgga
2221	attccaattgg	tcagaatcat	ttacaatgat	tggacacaga	tcaattacgt	gtattctatg
2281	agtatggacc	caactctccc	agtggtgtggc	aatagataaaa	cttaagaagt	gcaaatctac
2341	aaattttaatt	atacttgagg	aacatttaaa	aaacaagaag	gaattctgac	ataattctaa
2401	cataaggtca	agatgtagag	gaaaagaagg	atggatacac	acagtctgca	taaattggaag
2461	atgggatcca	gaagtgaaact	gctcaatggc	acaaatacaa	ttatgccac	ctccacctca
2521	gattcccaat	tctcacaata	tgacaaccac	actgaattat	cyggatggag	aaaaagtatc
2581	tgttctttgc	caagaaaaatt	atctaattca	ggaaggagaa	gaattacat	gcaagatggg
2641	agatggcgag	tcaataccac	tctgtgttga	aaaaattcca	gtttcacacc	caactcagat
2701	agaacacgga	accttaattt	catccaggtc	ttcacaagaa	agttatgcac	atggtgacta
2761	atttgagtat	actttgtgag	tgggtttcag	gatattctgaa	gaaatctgaa	caactcgtca
2821	catgggaaaa	tgaatttcaa	gaattcagtc	actgtgtaaat	cttctgtaaat	ctccacctga
2881	gattttctcat	gtgtttgtag	ctcacatgtc	agacagttat	cagtatggag	aagaagttac

9/10

```

2941 gtacaaatgt tttgaaggtt ttggaattga tgggcctgca attgcaaaat gcttaggaga
3001 aaaatgggtct caccctccat catgcataaa aacagattgt ctcagtttac ctagctttga
3061 aaatgccata cccatgggag agaagaagga tgtgtataag gcgggtgagc aagtgaactta
3121 cacttgtgca acatattaca aaatggatgg agccagtaat gtaacatgca ttaatagcag
3181 atggacagga aggccaaacat gcagagacac ctctgtgtg aatccgcccc cagtacaaaa
3241 tgcttatata gtgtcgagac agatgagtaa atatccatct ggtgagagag tacgttatca
3301 atgtaggagc ccttatgaaa tgtttgggga tgaagaagt atgtgtttaa atggaaactg
3361 gacggaacca cctcaatgca aagattctac aggaaaatgt gggccccctc cacctattga
3421 caatggggac attacttcat tcccgttgtc egtatatgct ccagcttcat cagttgagta
3481 ccaatgccag aacttgtatc aacttgagg taacaagcga ataacatgta gaaatggaca
3541 atggtcagaa ccacaaaat gcttacatcc gtgtgtaata tcccagagaa ttatggaaaa
3601 ttataacata gcattaaggt ggacagccaa acagaagctt tattcgagaa caggtgaatc
3661 agttgaattt gtgtgtaaac ggggatatcg tctttcatca cgttctcaca cattgcgaac
3721 aacatgttgg gatgggaaac tggagtatcc aacttgtgca aaaagataga atcaatcata
3781 aagtgcacac ctttattcag aactttagta ttaaatacgt tctcaatttc attttttatg
3841 tattgtttta ctcttttta ttcatacgta aaattttgga ttaatttgtg aaaatgtaat
3901 tataagctga gaccggtggc tctctt (SEQ ID NO 9)

```

FIG. 7 (cont.)

10/10

SEQ ID NO:10
 GENBANK ACCESSION NO. NP000177
 HUMAN COMPLEMENT FACTOR H

```

1  mrllakiicl mlwaicvaed cnelpprrnt eiltgswsdg typegtqaiy kcrpgyrsig
61  nvimvcrkge wvalnplrkc qkrpcghpgd tpfgtftltg gnvfeygvka vytcnegyql
121 lgeinyrecd tdgwtndipi cevvkclpvt apengkiyss amepdreyhf ggavrfvcns
181 gykiegdeem hcsddgfwsk ekpkcveisc kspdvingsp isqkiiyken erfqykcmng
241 yeysergdav ctesgwrplp sceekscdnp yipngdyspl rikhtgdei tyqcrngfyp
301 atrgntakct stgwipaprc tlkpcdypdi khgglyhenm rrpypfvavg kyysyycdeh
361 fetpsgsywd hihctgdgws pavpclrky fpylengynq nhgrkfvqgk sidvachpgy
421 alpkaqttvt cmengwsptp rcirvktcsk ssidiengfi sesqytyalk ekakyqcklg
481 yvtadgetsq sircgkdgws agptcikscd ipvfmmartk ndftwfknd tldyechdgy
541 esntgsttgs ivcgyngwsd lpicyerece lpkidvhlvp drkkdgykvq evlkfscckpg
601 ftivgpnsvq cyhfglspdl pickegvqsc gpppellingn vkektkeeyg hsevvveyyn
661 prflmkgpnk iqcvdgewtt lpvciveest cgdipelehq waqlssppyy ygdsvfncs
721 esftmighrs itcihgvtq lpqcvaiddl kckckssnlii leehlknkke fdhnsniryr
781 crgkegwihv vcingrwdpe vnscsmaqiql cppppqipns hmtttlnyr dgekvsvlq
841 enyliqegee itckdgrwqs iplcvkeipc sqppqiehgnt insrrssqes yahgtklsyt
901 ceggfrisee nettcmgkw sspqqceglp cksppeiishg vvahmsdsyq ygeevtykof
961 egfgidgpai akclgekwsd ppscktdcl slpsfenaip mgekdkdyka geqvtytcat
1021 yykmdgasnv tcinsrwtgr ptcdrtdscvn pptvqnayiv sqmskypsg ervryqcrsp
1081 yemfgdeevm clngnwtepp qckdstgkcg ppppidngdi tsfplsvyap assveyqcqn
1141 lyqlegnkri tcrngqwsep pkclhpcvis reimenynia lrwtakqkly srtgesvefv
1201 ckrgyrlssr shtlrrttcw d gkleypctak r (SEQ ID NO. 10)

```

FIG. 8